Making Healthcare More Accessible in Asia.

Zuellig Pharma provides world-class pharmaceutical distribution, digital and commercial services to support the evolving healthcare needs in the region.

Unlock the potential of Asia with Zuellig Pharma's unique healthcare solutions.

Select Marketdropdown carat
  • Australia
  • Brunei
  • Cambodia
  • China
  • Hong Kong & Macau
  • India
  • Indonesia
  • Japan
  • Korea
  • Malaysia
  • Myanmar
  • Philippines
  • Singapore
  • Taiwan
  • Thailand
  • Vietnam
Zuellig Pharma's depot in South Australia is a TGA-licensed facility that is approximately 1,300 sq.m. The facility has managed over 1,000 clinical trials since its foundation and currently manages more than 350 clinical trials.

Opportunities

  • Clinical Trial Supplies Market to reach USD 5.7B by 2027.
  • Healthcare CROs market in Australia and New Zealand valued at USD 1B in 2022.
  • CAGR of 11.5% expected for healthcare CROs market from 2023-2030.
  • Virtual clinical trials adoption to drive CRO industry growth in the region.
  • Clinical trials in Australia offer R&D tax advantages and cost efficiency, driving industry growth.

Capabilities

  • Global depot & cold chain logistics for reliable healthcare delivery.
  • Sophisticated temperature-controlled. infrastructure adhering to industry standards (GDP, GMP, CSV, HSE).
  • Smart Sourcing Solution for unparalleled access to medicine, incl. controlled drugs.
  • Specialised cold chain for temperature-sensitive materials.
  • Innovative patient-centric approach to clinical trials with depot-to-patient solutions.
Zuellig Pharma has a Brunei warehouse facility with an area of 7,330 sq.m. and a 225-pallet capacity for pharmaceutical, consumer, and medical device and diagnostics products. We serve over 90 healthcare customers nationwide, providing 100% coverage from government and private hospitals, specialist clinics, and chain pharmacies. Our certifications in Brunei for GDP, GDSP, and ISO 9001 (2015) ensure world-standard quality management system. Brunei's economic characteristics present immense business and tender opportunities, with a GDP of BND 5.8B as of Q3 2022 and 0.9% year-over-year growth, with a population size of approximately 450,000 as of 2022.

Opportunities

  • Brunei's government tenders make up 70% of healthcare business.
  • Thriving retail business with potential for chain pharmacy expansion.
  • Growing oncology opportunities in public and private sectors.
  • Potential for Brunei's Ministry to plan, promote, and develop medical tourism.
  • Increasing demand for health and medical services due to ageing population.

Capabilities

  • Leading healthcare provider in Brunei with 36 years of experience as only foreign invested company.
  • Largest distributor and market leader, serving 9 of top 10 pharma clients in Brunei.
  • Excellent RA capabilities, holding market authorisation for 25% of registered medicinal products with MOH.
  • Innovative, automated warehouse system handles 80% of biologics and cold chain products in Brunei.
  • Robust tender management team with excellent track record in handling MOH tenders at scale.
Zuellig Pharma's Cambodia facilities offer a newly-built distribution centre with an over 6,300 sq.m. warehouse and 1,200 sq.m. mezzanine for healthcare products, including 6,400 pallets in 6-high racking and 240 cold room storage pallets. With 90% coverage of ethical, pharmacy, and modern trade, we serve over 10,000 healthcare customers nationwide, including hospitals, clinics, and pharmacies, through 200 sales and marketing representatives. Our quality of work is recognised with certifications such as GDSP, GMP, GDPMDD, and ISO 9001:2015.

Opportunities

  • Expansion of universal healthcare boosts medical services utilisation.
  • NGOs continue to provide essential medicines.
  • Basic medicines are vital due to regional production and low domestic manufacturing.
  • Total pharmaceutical sales reached USD 386M in 2022 with per capita spending at USD 23.
  • Pharmaceutical consumption rises to treat growing prevalence of chronic lifestyle diseases.

Capabilities

  • Zuellig Pharma has 20 years' experience as healthcare provider in Cambodia, serving four top 10 Pharma clients.
  • Largest cold-room facility in Cambodia with state-of-the-art infrastructure for healthcare.
  • Proven cold chain tech maintains optimal quality during delivery.
  • Passive packaging with unique thermal isolation chamber system.
  • Patient-centric affordability and adherence programs.
  • Custom mobile app for client program admin, enrolments, and updates.
Zuellig Pharma China's Beijing facility, with 20 years of clinical supply experience, is GDP/GMP compliant and a trusted partner for various clients in clinical trials, including pharmaceutical companies, CROs, CMOs, biopharmaceutical firms, medical device companies, and diagnostic firms.

Opportunities

  • China's pharmaceutical market to reach USD 161.8B by 2023, accounting for 30% of global market.
  • Ageing population and increased life expectancy driving rising demand for healthcare in China.
  • Pharma sales in China projected to grow by 4.04% in 2022 and 3.58% in 2023.
  • Chinese government promoting industry consolidation to regulate and control drug pricing.
  • China imports biotechnology pharmaceuticals to meet growing domestic demand.

Capabilities

  • Reliable global cold chain logistics network
  • Sophisticated GDSP and GMP temperature-controlled facilities
  • Smart sourcing solution for unparalleled medicine access
  • Specialised cold chain solutions for sensitive materials in clinical storage
  • Central distribution service for global studies
  • Tailored repackaging services with multilingual labels
Zuellig Pharma has two warehouses in Hong Kong spanning over 48,000 sq.m., offering air-conditioned storage for 24,000 pallets and cold chain storage for 800 pallets. We serve 10,000+ healthcare customers, including hospitals, clinics, dentists, and drug stores. Zuellig Pharma moves 48,000 cubic meters of products annually and has won awards such as the HR Distinction Awards - Excellence in Employee Wellbeing and Occupational Health Award - Excellence Award of Joyful@Healthy Workplace Best Practices Award.

Opportunities

  • Opportunities in China GBA for Hong Kong drugs and medical devices in public hospitals
  • Predicted 3.5%-5.5% economic growth for Hong Kong in 2023
  • High life expectancy in Hong Kong due to advanced healthcare and health consciousness
  • Aging population driving demand for healthcare services and products
  • Increased demand for consumer health post-COVID-19 due to raised health consciousness
  • Smart hospitals and tele-health offer innovative and sustainable solutions for growing service demand.

Capabilities

  • Over 40 years healthcare experience in Hong Kong
  • Expert in healthcare solutions from storage to delivery
  • Specialised in cold chain storage and distribution with certified facilities
  • Over 20 years of vaccine and vaccination program experience
  • Strong relationships with top healthcare companies in Hong Kong & Macau
  • DoH approved and GMP certified secondary repackaging facilities.
Zuellig Pharma's facility in India is strategically-located in Mumbai to ensure that products and services are made available with the shortest leadtime. Covering over 1,530 sq.m., the facility offers one-stop solutions for every client's clinical trial needs, including a global depot and cold chain logistics network with temperature-controlled infrastructure and GDSP and GMP facilities for fast product and service availability. India is a cost-efficient and profitable market for major pharma, and biotech companies, as well as CROs, with local models meeting country standards.

Opportunities

  • Clinical trial industry in India to grow at 8.2% per annum until 2030.
  • Consistent patient population and easy access to modern medical technology in India.
  • India offers a favorable currency exchange rate for pharma and biotech companies.
  • Major pharma and biotech companies and CROs operate in India, incorporating local models to meet country standards, making it a cost-efficient and profitable market.

Capabilities

  • Zuellig Pharma has a global depot and cold chain logistics network with advanced temperature-controlled facilities and GDSP and GMP facilities.
  • Smart Sourcing Solution provides access to medicines and ancillaries, including controlled drugs.
  • Specialised cold chain solutions available for temperature-sensitive materials.
  • Strong Quality Management System (QMS) and operational excellence processes with a qualified team to offer CTSM services.
Zuellig Pharma provides complete coverage of ethical, pharmacy, and modern trade products in Indonesia, serving over 26,000 direct outlets with over 2,800 trained employees, 25 warehouses, 4 sales offices, and 8 APL partners' locations. The team has amassed numerous accolades, such as the HR Asia Best Companies to Work for in Asia and CNBC Indonesia Outstanding Company in Sustainability-Community Initiative awards.

Opportunities

  • Indonesia launched its first digital health blueprint, aiming to expand inclusive healthcare coverage for its 270M population.
  • The blueprint will help Indonesia accelerate its national goal of providing universal, affordable, equitable and quality care to all its citizens, using digital technologies.

Capabilities

  • Zuellig Pharma offers integrated healthcare solutions in Indonesia, including distribution, commercialisation, patient care, data analytics, and importation.
  • APL National Distribution Centre is the largest Pharma-grade warehouse in Indonesia, with 54,000 sq.m. space for pharma, consumer, and medical products.
  • Over 13,000 orders are handled daily by 550 certified personnel, with 6,000 orders delivered via 200+ vehicles.
  • The highest cold chain standards in Indonesia, with over 2,000 sq.m., 33 cold rooms, and 85 chillers.
Zuellig Pharma has an impressive partner depot facility in Japan, covering a total area of around 1.2 million sq.m., out of which 300,000 sq.m. are solely dedicated to pharmaceutical handling. Apart from its extensive size and specialisation, the partner depot also prioritises sustainability, evident through the installation of solar power generation systems and nighttime heat storage type air conditioning systems in all its offices.

Opportunities

  • Japan's ¥10-trillion (USD 75B) national endowment fund signals growth in healthcare industry.
  • Japan accounts for 4.7% of global clinical trial activity in 2022.
  • Japan's developed healthcare system and ageing population increase demand for new treatments.
  • Sakigake package accelerates drug and device approvals in Japan.
  • Japanese Ministry of Health promotes innovation in pharmaceutical manufacturing.

Capabilities

  • Partner depot in Japan obtained Green Management Certificate.
  • Global logistics network with depots and cold chain infrastructure.
  • Facilities comply with GDSP and GMP standards and offer advanced temperature control technology for cold chain solutions.
  • Smart Sourcing Solution for exclusive access to medicines and controlled drugs.
  • High standards of quality maintained, meeting GDP, GMP, CSV, and HSE requirements.
Zuellig Pharma's Korea facilities comprise 12 warehouses and a team of 150 sales and marketing representatives serving over 36,000 healthcare customers nationwide. We have received various accolades and certifications for sustainability, transparency in pharmaceutical distribution, and industry leadership.

Opportunities

  • Strong healthcare system and popular medical tourism market.
  • Booming digital health sector with patient-focused innovation.
  • High purchasing power and one of the highest GDP per capita in APAC region.
  • Rapidly expanding pharmaceutical industry with USD 17.9B reach and 9.6% CAGR in 2021.
  • Thriving medical device industry with USD 7.9B reach and 10.6% CAGR in 2021, ranking 9th globally.
  • Ageing population with growing healthcare demands.
  • Increasingly recognised as a key destination for clinical trials in the Asian pharmaceutical market.

Capabilities

  • 25 years experience as a healthcare service provider in South Korea.
  • Operate South Korea’s largest cold-room facility.
  • South Korea’s largest specialty and vaccine distributor, and Asia’s clinical logistics leader.
  • Preferred go-to commercialisation partner for high compliance standards and transparency.
  • Customised technology solutions for eCommerce, block-chain, and business analytics.
Zuellig Pharma's Malaysia facilities include a main warehouse in Bukit Jelutong and an approximately 7,000 sq.m. warehouse for dialysis solutions, medical supplies, and surgical lenses. With two branch offices and a branch warehouse, Zuellig Pharma has 100% coverage of hospitals, clinics, and pharmacies with over 15,000 customers across Malaysia. We have won numerous awards for quality and certifications.

Opportunities

  • Quality healthcare system, top global medical tourism market.
  • Growing patient-centric digital health innovation in Malaysia.
  • High allocation from Budget 2023 for healthcare.
  • Medical device industry to reach USD 2.2B in 2023.
  • Ageing population driving increasing demand for healthcare services.

Capabilities

  • 84 years experience as healthcare provider in Malaysia.
  • Largest cold chain facility, eZCooler as an advanced passive packaging solution.
  • End-to-end integrated solutions for entire healthcare value chain.
  • Actively drive sustainability and partner with clients on special projects to meet carbon savings objectives.
Zuellig Pharma's Myanmar facilities provide comprehensive coverage of ethical, pharmacy, and modern trade services with over 90% reach. Our facilities are certified in GDSP, GMP, and ISO, ensuring top-quality cold chain facilities, passive packaging, and patient-centric programs for affordability and adherence. With over 4,000 healthcare customers nationwide and a team of 90 highly-trained sales representatives, we offer exceptional service.
  • National health insurance system reduces healthcare expenses and improves accessibility.
  • Companies Act encourages foreign investment in the pharmaceutical sector.
  • National efforts combat malnutrition, undernutrition, and obesity through health and educational programs.
  • International aid packages boost local health facilities in combating COVID-19.
  • Zuellig Pharma has 8 years of experience in Myanmar, serving 6 out of the top 10 pharma clients.
  • Our top-notch cold-room facilities use advanced infrastructure.
  • Our cold chain transport tech and packaging use thermal isolation chambers for quality maintenance.
  • We provide patient-centric solutions for affordability and adherence.
  • Custom mobile apps are available for client program administration and real-time updates.
Zuellig Pharma in the Philippines has seven distribution warehouses covering over 59,000 sq.m. of distribution centre space for pharma, consumer, medical devices, and diagnostics products. We have over 1,700 employees nationwide and have distributed to over 19,000 physicians, 700 private hospitals, 7,000 chain drug stores, and more. We have been recognised for our quality of work and sustainability efforts.

Opportunities

  • Ophthalmology agency business shows consistent growth building on B&L.
  • Diagnostic and consumable business is rapidly growing, currently 53% SOB in MDI.
  • Animal health business is rapidly growing, especially in the pet segment.
  • Capitalising on client relationships to drive commercialisation initiatives.
  • Potential to improve awareness and utilisation of value-added services (VAS) for higher operating revenue and client conversion.

Capabilities

  • Over 100 years of experience in pharma distribution in the Philippines.
  • 100% coverage of hospitals, pharma, modern trade accounts & 50k+ customers nationwide.
  • Strong market presence in 86 therapeutic classes.
  • Wide range of services incl. Repackaging, Samples Distribution, Product Destruction & Trade Marketing (CHC).
  • Innovative tech solutions incl. eZHealth, eZRx & e-Commerce solutions.
  • Patient-centric programs for adherence, access & affordability.
Zuellig Pharma's Singapore facilities cover over 44,000 sq.m. across three warehouses and serve over 6,000 healthcare customers with extensive ethical, pharmacy, and modern trade coverage. We have received various accolades and certifications, such as the HR Asia Best Companies to Work (2020) for Singapore, IDC Future Enterprise Awards (2022), and National Awards (COVID-19) 2022 recipient for President's Certificate of Commendation for Singapore.

Opportunities

  • Top destination for medical tourism with excellent healthcare.
  • Singapore driving patient-centred innovations in digital health.
  • High GDP per capita reflects strong purchasing power in APAC.
  • Medical device industry projected to reach USD 3.5B by 2022.
  • Increasing demand for health services due to ageing population.

Capabilities

  • Zuellig Pharma delivers 85+ years of healthcare excellence in Singapore.
  • Largest cold-room facility with innovative infrastructure.
  • Top secondary repackager with serialisation capability.
  • Patient-centric programmes for affordability and adherence, with custom mobile app.
  • Tailored technology solutions for eCommerce, blockchain and analytics.
Zuellig Pharma in Taiwan boasts five warehouses spanning over 65, 000 sq.m. and catering to pharmaceuticals, consumer goods, and medical devices. We offer 100% coverage of ethical, pharmacy, and modern trade services, serving 20,000+ healthcare customers with over 200 sales and marketing representatives. We have received accolades like the National Healthcare Quality Award and National Biotechnology and Medicine Care Quality Award.

Opportunities

  • National health insurance budget growing at 2.9% - 4.5% annual rate.
  • Strong digitalisation trend in health sector, particularly in telemedicine and AI diagnosis.
  • Mature environment for clinical trials phases 1-3.
  • Government-funded local biotech companies researching and manufacturing.
  • Increasing healthcare demands due to ageing population and low fertility rate.

Capabilities

  • Over 35 years of healthcare experience in Taiwan.
  • Strong relationships with 90+ multinational healthcare companies.
  • Taiwan's only ultra-low cold chain system and largest cold chain storage.
  • Patient care team of 50 nurses serving 60,000+ patients.
  • Customised eZ-solution app for program administration and real-time updates.
Zuellig Pharma runs four warehouses in Thailand, with 56,400 pallet storage space and a full range of temperature-controlled cold chain rooms for various products. We offer 98% customer coverage of ethical, pharmacy, and OTC, serving over 22,000 healthcare customers with 500 sales and marketing representatives, and have distributed 87% of vaccines to date. We have received numerous accolades, including nine awards at the 2022 TCCTA Contact Center Awards.

Opportunities

  • Rising demand for healthcare due to increased focus on personal health and COVID-19.
  • Ageing population in Thailand leads to increased treatment for chronic diseases.
  • Universal Health Coverage scheme provides broad coverage, with return of foreign patients.

Capabilities

  • Zuellig Pharma has 75+ years of healthcare experience in Thailand.
  • Largest cold-chain facility for healthcare products with various temperature protocols.
  • Fleet of air-conditioned transportation vans with innovative eZCooler packaging.
  • One-stop-service for redressing under GMP.
Zuellig Pharma's Vietnam facilities comprise five warehouses with over 23,000 AC pallets and 1,700 CC pallets, catering to various healthcare products. We provide 100% coverage across all medical channels, serving over 60,000 healthcare customers. Our certifications include GDP, GCP, GMP, GSP and GSDP, GDPMD, ISMS, and ISO.

Opportunities

  • Ageing population drives long-term demand for prescription drugs.
  • Growing middle class leads to increasing demand for quality healthcare services.
  • Significant contribution from imported pharmaceuticals, APIs, and medical devices.
  • Abundance of M&A opportunities across healthcare verticals.

Capabilities

  • Over 30 years healthcare service experience in Vietnam.
  • Facilities in Vietnam meet FM Global Platinum standards and use efficient energy features.
  • Patient-centric programs for affordability and adherence.
  • 100% direct tender penetration and 99% sales coverage through call plans for retail channels.
  • Comprehensive ordering platforms and technology consulting services. 

Solutions

At Zuellig Pharma, we bridge the gap between clients and customers in the healthcare value chain by providing customised and innovative healthcare solutions that ensure unbeatable access to care throughout Asia.
Menuinner page nav menu
  • Distribution
  • ZP Therapeutics
  • Clinical Reach
  • Technology Solutions
  • Patient Solutions
tab image
State-of-the-art end-to-end distribution solutions across 13 markets
Distribution
Experience unparalleled access to the healthcare market with Zuellig Pharma. Our comprehensive range of pharmaceutical distribution services and tailored healthcare solutions empower your business to reach its full potential. As a trusted leader in the industry, Zuellig Pharma delivers custom healthcare solutions that meet your unique needs.
Discover More
tab image
Understands consumers, customers and market in Asia
ZP Therapeutics
Zuellig Pharma is your trusted commercialisation partner in the healthcare industry. We specialize in delivering innovative pharma solutions to enhance patient access to care. Our flexible partnership models cater to diverse client needs. With extensive expertise in Asia, we provide regulatory and governmental affairs support, along with sales and marketing strategies to help businesses expand their reach and impact.
Discover More
tab image
The future of clinical trials is brighter than ever.
Clinical Reach
Partner with Zuellig Pharma for seamless management of clinical trial supply chains. From regional studies to complex global multi-center trials, our expertise spans diverse scales. With our global product sourcing, integrated storage and pharmaceutical distribution solutions, and localized returns management, we ensure compliance with local and international healthcare regulations for your clinical needs.
Discover More
tab image
Your digital platform of choice
Technology Solutions
Revolutionise Asia's healthcare ecosystem with Zuellig Pharma's innovative pharmaceutical software platforms. Our advanced solutions bridge the gaps, enhancing access and outcomes for clients, healthcare professionals, and patients. With cutting-edge technology, businesses can streamline operations, expand their reach, and deliver the care patients deserve.
Discover More
tab image
Personalised and innovative healthcare support
Patient Solutions
Experience patient-centric care with Zuellig Pharma's Patient Solutions platform. Our personalised healthcare solutions and support empower patients to take control of their well-being. With innovative features like mobile apps, home care services, and disease management programs, we enhance the patient experience and improve health outcomes.
Discover More

Segments

Long and lasting relationships with leading healthcare pharmaceutical companies across multiple industry verticals.
image

Get in Touch

Reach out to us today and start a conversation.
Contact Us

Technology Solutions

Digital technologies are at the core of our services. Learn how governments and partner companies are driving efficiency and effectiveness with Zuellig Pharma.

eZTracker

eZTracker by Zuellig Pharma is an advanced supply chain management solution that helps businesses track and monitor their healthcare products in real-time.
Visit eZTracker

eZRx

eZRx by Zuellig Pharma is a cutting-edge platform that streamlines pharmaceutical ordering and delivery processes. eZRx enables seamless communication between healthcare professionals and suppliers for efficient & effective medication management.
Visit eZRx

About Us

We provide world-class distribution, technology, commercial, and integrated health solutions and services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multi-billion dollar business covering 16 markets with over 12,000 employees.
Learn about Zuellig Pharma

Sustainability

At Zuellig Pharma, we prioritise sustainability for a healthier future through ethical business practices, resource conservation, and community support. Our EcoVadis Platinum Rating for 2023 showcases our dedication to pursuing a better tomorrow for our generation and beyond.
See Our Impact

News and Insights

Discover what Zuellig Pharma is doing across the globe.

Zuellig Pharma and Karo Healthcare strengthen partnership across key markets in Asia

<p style="margin-bottom: 8px;"><span><strong>SINGAPORE, 18 March 2024</strong> &ndash; Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that it has expanded its commercialisation partnership with Karo Healthcare (&ldquo;Karo&rdquo;). Founded in 1987, Karo is a leading European consumer healthcare company headquartered in Stockholm, Sweden, with products available in more than 90 countries.&nbsp;&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 8px;"><span>Under the new agreement, Zuellig Pharma will be the exclusive commercialisation partner for Karo&rsquo;s over-the-counter (OTC) brand Lamisil&reg;, a product for the treatment of fungal infections, across Hong Kong, Malaysia, Philippines, Singapore, South Korea, Taiwan and Vietnam. With industry-leading coverage across healthcare professionals and retail pharmacies in Asia and in-market commercial expertise, ZP Therapeutics, the commercial division of Zuellig Pharma, will be steering this partnership.&nbsp;&nbsp;&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 8px;"><span>Zuellig Pharma has had a strong commercialisation partnership with Karo since 2019 for its product portfolio in the Philippines, Vietnam, Singapore and Indonesia.&nbsp;&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px;"><span>&ldquo;We are excited to work with Karo to expand access and availability of its products. As an integrated healthcare solutions company, this partnership will also play a key role in the strengthening of Zuellig Pharma&rsquo;s consumer health portfolio as we grow in key markets such as Korea and Taiwan,&rdquo; said John Graham, Group CEO, Zuellig Pharma. &ldquo;I&rsquo;m confident that ZP Therapeutics&rsquo; extensive partner network and proven commercial expertise will be critical in facilitating greater access for in-demand consumer healthcare products in Asia.&rdquo;&nbsp;&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px;"><span>&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px;"><span><strong>About Zuellig Pharma</strong>&nbsp;<br /> <br /> </span></p> <p style="margin-top: 0px; margin-bottom: 8px;"><span><strong>Zuellig Pharma</strong> is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.&nbsp;&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 8px;"><span><strong>ZP Therapeutics</strong>, a division of Zuellig Pharma, is the commercialisation partner of choice for the healthcare industry with offices in 13 countries across Asia and over 2,500 associates. A catalyst in improving patient journeys and healthcare outcomes through commercial excellence, robust in-market capabilities and strong ethical principles, ZP Therapeutics is a trusted partner for expanding patient access and providing innovations to the healthcare community.&nbsp;&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px;"><span>For more information, visit: </span><a href="https://www.zuelligpharma.com/" rel="noopener noreferrer" title="https://www.zuelligpharma.com/" target="_blank">https://www.zuelligpharma.com/</a><span style="color: #1e53a3;"></span></p> <p style="margin-top: 0px; margin-bottom: 0px;"><span style="color: #1e53a3;">&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 8px;"><span><strong>Zuellig Pharma Contact Information&nbsp;</strong>&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px;"><span>Angelene Chong&nbsp;&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px;"><span>Zuellig Pharma&nbsp;&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px;"><a href="mailto:achongam@zuelligpharma.com" rel="noopener noreferrer" title="mailto:achongam@zuelligpharma.com" target="_blank">achongam@zuelligpharma.com</a><span></span></p> <p style="margin-top: 0px; margin-bottom: 0px;"><span>&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px;"><span>Sandpiper&nbsp;&nbsp;</span></p> <p style="margin-top: 0px;"><a href="mailto:zuelligpharma@sandpipercomms.com" rel="noopener noreferrer" title="mailto:zuelligpharma@sandpipercomms.com" target="_blank">zuelligpharma@sandpipercomms.com</a><span>&nbsp;&nbsp;</span></p>

Zuellig Pharma and Viengthong Pharma Forge Strategic Partnership to Enhance Healthcare Accessibility in Laos

<div class="OutlineElement Ltr SCXW163730102 BCX0" style="color: #000000; background-color: #ffffff; margin: 0px; padding: 0px;"> <p class="Paragraph SCXW163730102 BCX0" paraid="6" paraeid="{22cd5c6d-95e9-4058-80ca-fd021868a008}{95}" style="color: windowtext; background-color: transparent; margin-right: 0px; margin-left: 0px; padding: 0px; text-align: justify;"> <p style="margin-bottom: 0px; margin-left: 0px;"><span>VIENTIANE CAPITAL, 12 March 2024 &ndash;&nbsp; Zuellig Pharma, a leading healthcare solutions company in Asia, and <span style="color: #000000; background-color: #ffffff; text-align: justify;">Viengthong Pharma, a leading pharmaceutical company in Laos,&nbsp;</span>proudly announce their strategic partnership aimed at making healthcare more accessible across Laos.&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;">&nbsp;</p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;"><span>This collaboration signifies a pivotal milestone in advancing healthcare infrastructure in Laos. By leveraging the expertise and resources of both organisations, the partnership aims to address critical healthcare challenges, particularly in underserved regions, and improve the overall quality of healthcare services available to the people of Laos, aligning with the key objectives of the Ministry of Health of Laos PDR.&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;">&nbsp;</p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;"><span dir="ltr" class="ui-provider a b c d e f g h i j k l m n o p q r s t u v w x y z ab ac ae af ag ah ai aj ak">The signing ceremony was attended by <strong>BG Dr. Buasing Inthavong, Deputy of the General Logistic Department, Minister of National Defence of the Lao PDR, Commander of Medical Areas in Military</strong>, and esteemed representatives from both Viengthong Pharma, led by Mr. Shihamano Bannavong, the CEO of Viengthong Pharma, and Zuellig Pharma, led by Jan Rask Christensen, Managing Director of Cambodia, Myanmar and Laos. They were joined by key stakeholders from the government, including representatives from Ministry of Health, private sector and NGOs.</span></p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;">&nbsp;</p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;"><span>As part of the strategic partnership, Viengthong Pharma and Zuellig Pharma will collaborate on various initiatives, including the distribution of pharmaceutical products, the implementation of healthcare infrastructure projects, and the development of educational programmes aimed at raising awareness about key health issues.&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;">&nbsp;</p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;"><span>"We are thrilled to embark on this transformative journey with Zuellig Pharma," said Mr. Shihamano Bannavong, CEO of Viengthong Pharma. "Together, we are dedicated to breaking barriers and expanding access to essential healthcare services across Laos, ensuring that every individual has the opportunity to lead a healthy and fulfilling life. Additionally, with the GSDP certification, we are confident in collaboratively working with Zuellig Pharma to better leverage healthcare access in Laos."&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;">&nbsp;</p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;"><span>Jan Rask Christensen, Managing Director of Cambodia, Myanmar and Laos echoed this sentiment, stating, "This partnership exemplifies our shared vision and is very much in line with Zuellig Pharma&rsquo;s mission of making healthcare more accessible to the communities we serve. By combining our strengths and resources, we are determined to make a meaningful difference to the lives of the people in Laos."&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;"><span>&nbsp;&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;">&nbsp;</p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;"><span><strong>About Viengthong Pharma</strong>&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;"><span>Viengthong Pharmacy was established in 1992 by <strong>Mr. Thongpheuane Khantivong</strong>, the president of Viengthong Pharma. We are a wholesale distributor specializing in importing and distributing pharmaceutical products, medical equipment, cosmetics, and consumer goods with high quality to public and private hospitals, clinics, pharmacies, and retailers nationwide, serving more than 1,000 customers in Laos. We also provide consultancy services and can be engaged as a pharmaceutical distribution partner in the healthcare sector with expertise in compliance, regulatory affairs, and market access, offering comprehensive solutions to enhance healthcare delivery and improve patient outcomes in the Lao PDR.&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;"><span>Website: Viengthong Pharma (<a rel="noopener noreferrer" href="https://vtmedpharma.la/" target="_blank">vtmedpharma.la</a>).&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;"><span>&nbsp;&nbsp;</span></p> <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 0px;"><span><strong>About Zuellig Pharma</strong>&nbsp;</span></p> <p style="margin-top: 0px; margin-left: 0px;"><span>Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.&nbsp;<br /> <br /> <p style="color: #000000; background-color: #ffffff; margin-bottom: 0px; margin-left: 0px; text-align: justify;">For media enquiries or further information regarding the strategic partnership between Viengthong Pharma and Zuellig Pharma, please contact:&nbsp;</p> <p style="color: #000000; background-color: #ffffff; margin-top: 0px; margin-bottom: 0px; margin-left: 0px; text-align: justify;">&nbsp;&nbsp;</p> <p style="color: #000000; background-color: #ffffff; margin-top: 0px; margin-bottom: 0px; margin-left: 0px; text-align: justify;">Marketing Department&nbsp;</p> <p style="color: #000000; background-color: #ffffff; margin-top: 0px; margin-bottom: 0px; margin-left: 0px; text-align: justify;">Viengthong Pharma Import-Export Sole Co., Ltd&nbsp;</p> <p style="color: #000000; background-color: #ffffff; margin-top: 0px; margin-bottom: 0px; margin-left: 0px; text-align: justify;">info@vtpharma.la&nbsp;</p> <p style="color: #000000; background-color: #ffffff; margin-top: 0px; margin-bottom: 0px; margin-left: 0px; text-align: justify;">(856 21) 240 350, (856 21) 250 132, (856 21) 214 547&nbsp;</p> <p style="color: #000000; background-color: #ffffff; margin-top: 0px; margin-bottom: 0px; margin-left: 0px; text-align: justify;">&nbsp;&nbsp;</p> <p style="color: #000000; background-color: #ffffff; margin-top: 0px; margin-bottom: 0px; margin-left: 0px; text-align: justify;">Angelene Chong&nbsp;</p> <p style="color: #000000; background-color: #ffffff; margin-top: 0px; margin-bottom: 0px; margin-left: 0px; text-align: justify;">Zuellig Pharma&nbsp;</p> <p style="color: #000000; background-color: #ffffff; margin-top: 0px; margin-left: 0px; text-align: justify;">achongam@zuelligpharma.com&nbsp;</p> </span></p> </p> </div> <div class="OutlineElement Ltr SCXW163730102 BCX0" style="color: #000000; background-color: #ffffff; margin: 0px; padding: 0px;"> <p class="Paragraph SCXW163730102 BCX0" paraid="38" paraeid="{bba4c32d-73b6-4a12-9820-018e6226d532}{40}" style="color: windowtext; background-color: transparent; margin-right: 0px; margin-left: 0px; padding: 0px; text-align: justify;"><span style="font-family: arial;"></span></p> <p class="Paragraph SCXW163730102 BCX0" paraid="38" paraeid="{bba4c32d-73b6-4a12-9820-018e6226d532}{40}" style="color: windowtext; background-color: transparent; margin-right: 0px; margin-left: 0px; padding: 0px; text-align: justify;"><span class="EOP SCXW163730102 BCX0" data-ccp-props="{'201341983':0,'335551550':6,'335551620':6,'335559740':276}" style="margin: 0px; padding: 0px; line-height: 24.15px; font-family: arial;"></span></p> </div>

Importance of driving the need for innovative and efficient solutions across the healthcare value chain

<p style="color: #212529; background-color: #ffffff; margin-bottom: 1rem;"><span><em><strong>by John Graham, Group CEO, Zuellig Pharma</strong></em></span><br /> &nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;"><img alt="" height="150" width="150" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Healthcare-Providers/Importance-of-driving-the-need-for-innovative-and-efficient-solutions-across-the-healthcare-value-chain/Zuellig-Pharma-CEO-John-Graham-supply-chain-optimisation-resilience.jpg" /><br /> <br /> Change is perennial in the healthcare industry. With evolving patient needs, emerging disease areas and new innovations driving this fast-moving landscape, we need to collectively prioritise access to healthcare, affordability and sustainability to benefit the health of communities across Asia.<br /> &nbsp;<br /> <img alt="" height="667" width="1000" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Healthcare-Providers/Importance-of-driving-the-need-for-innovative-and-efficient-solutions-across-the-healthcare-value-chain/zuellig-pharma-ceo-healthcare-value-chain.png" /></p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">This, alongside collaboration among key stakeholders, is key to ensuring continued access to healthcare across communities in Asia.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">From the discovery of insulin and penicillin in the early 20th century, the pharmaceutical industry has come a long way in meeting the healthcare needs of the world&rsquo;s populations. Rapid research and development of innovative drugs and therapies have countered the emergence of new diseases that threaten to have dire impacts on communities, especially those unequipped to address them.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">However, with every new year that brings unprecedented opportunities for the industry, the landscape also grapples with the impact that external economic forces have on delivering healthcare. Inflationary pressures, rising costs and geopolitical headwinds have all had an impact on many industries, and the pharmaceutical sector is no different. There is a need for sustainable, innovative and efficient solutions across the healthcare value chain and it is critical that the industry stays focused on the end goal of providing greater access to high-quality healthcare for the people who need it most.<br /> <br /> <span><strong>Complex challenges hindering access to healthcare in an evolving landscape</strong></span></p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">In a region as diverse as Asia, the challenges faced by each market in making healthcare affordable and accessible are as unique as the populations that live in them. With rising healthcare costs, changing regulatory and compliance standards and fragmented medical supply chains, ensuring that patients are able to access the medicines they need has been an uphill task for manufacturers, distributors, and healthcare professionals.<br /> <br /> <span><strong>Affordability and inequitable distribution among developing and developed nations</strong></span></p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Access to emerging innovations in the pharmaceutical space has been largely out of reach for developing nations, with reimbursement systems at varying levels of maturity in the region, placing greater burdens on the patient to pay out-of-pocket. With different levels of health financing from local governments as a result of a dependence on economic growth, the sustainability of widespread healthcare access can be challenging.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">During the pandemic, many discussed the delay in access to vaccines for developing nations. Countries ranking lowest in GDP per capita were found to have waited the longest for COVID-19 vaccines as opposed to those with larger economies, despite the pandemic being indiscriminate in its toll on populations. Vaccine nationalism and a lack of universal healthcare have been two of the biggest reasons for why access across Asia Pacific was disparate, and three years on from the pandemic, access to the newest drugs and healthcare innovations paints a parallel picture.<br /> <br /> <span><strong>Gaps in global healthcare supply chains</strong></span></p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">The last few years have revealed vulnerabilities in global medical supply chains, and several key challenges continue to make the delivery of healthcare less resilient to external shocks.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Supply networks have become more exposed to demand and supply fluctuations as a result of production concentration and a lack of diversification of supply sources. Extensive offshore sourcing of critical materials has also made supply chains more complex and fragmented, putting critical healthcare products at higher risk of production stoppages when faced with border closures.<br /> <br /> Product availability is hindered when faced with no-fly zones during geopolitical turmoil, and natural disasters such as flash floods and earthquakes which can cause severe consequences for the ability to manufacture much needed healthcare supplies and products due to shortages in inputs. When coupled with protectionist measures and the imposition of movement limitations during exceptional circumstances, it is evident that the global medical supply chain is not prepared for long-term resilience.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">In order to provide the high-quality care patients need, the intricate and complex web of suppliers, distributors, regulatory bodies and local healthcare providers need to ensure that they are properly resourced, and resistant to external shocks in the event of supply deficiencies or a spike in demand. Boosting supply reliability, operational efficiencies and ensuring that systems remain agile will be crucial.<br /> <br /> <span><strong>Modern solutions for modern problems</strong></span></p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">From manufacturers and distributors, to healthcare providers, ensuring sustainable access to healthcare for patients requires a collective effort. It is critical that businesses in the industry work collaboratively towards a shared goal of strengthening health systems and healthcare delivery. Rome was not built in a day, and the same applies for solutions that are geared to solve complex, evolving challenges.<br /> <br /> <img alt="" height="399" width="600" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Healthcare-Providers/Importance-of-driving-the-need-for-innovative-and-efficient-solutions-across-the-healthcare-value-chain/zuellig-pharma-supply-chain-modern-solutions.jpg" /></p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;"><span><br /> <strong>The importance of cross-sector collaboration and supply chain resilience</strong></span></p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">In order to ensure that healthcare access is equitable and affordable, organisations in both the private and public sector need to be proactive in cultivating the right relationships, driven by shared goals. From the research and development process to the launch of drugs in far reaching markets, industry players have a hand in ensuring that the patient remains at the centre of their purpose. At both ends of the drug life cycle, strong partnerships between manufacturers, regulatory bodies and governments can help to ensure that developing nations are not left behind.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">For example, ensuring that the right logistics, infrastructure and processes are in place to support global clinical trials in underrepresented markets can play a critical role in ensuring diversity in the R&amp;D process. However, with increasing complexity of supply chain management, and new emerging therapies that require specialised methods of handling, ensuring that clinical needs are compliant with both local and international regulations will involve experience, knowledge and partnership between multiple stakeholders.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">On the other end of the spectrum of drug delivery, cross-sector collaboration can help to circumvent issues in access when trade grinds to a halt during border closures, or when supply chains are threatened due to geopolitical incidents. At the same time, it is important that supply chains are further strengthened with greater end-to-end visibility to adequately address risks and produce contingencies for potential shocks. Diversifying sourcing for important commodities required in&nbsp;production between offshore and domestic suppliers can also play a critical role in making supply chains more resilient especially during times of crisis.<br /> <br /> <img alt="" height="667" width="1000" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Healthcare-Providers/Importance-of-driving-the-need-for-innovative-and-efficient-solutions-across-the-healthcare-value-chain/zuellig-pharma-collaboration-supply-chain-resilience.jpg" /></p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;"><span><strong>Introducing innovative and efficient methods of delivery</strong></span></p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">As consumer behaviour evolves, this too, necessitates the need for newer methods of drug delivery. Digital solutions will support patient autonomy and the increased accessibility for personalised care, but changing regulatory landscapes will continue to shape the way businesses such as telehealth and e-pharmacies operate and grow. Governments and regulators need to work hand in hand with businesses to ensure that the potential of such solutions can be tapped for the betterment of patient access, while ensuring that they remain transparent and accountable to users and the environment they operate in.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Patent cliffs and emerging advanced therapies have also had an important influence on the portfolios of manufacturers, and while these challenges remain for the industry to reconcile, ensuring that the supply chain evolves to encompass such changes will also be critical. Utilising new-generation technologies that go beyond traditional cold chain capabilities, that can support and monitor variable temperatures and provide real-time insights at every step of the delivery journey will have a profound impact on the supply chain. Concurrently, equipping distributors with the right expertise to make the necessary infrastructure and process shifts to accommodate such changes will have a lasting impact on ensuring the integrity of medicines to even the most remote communities.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">It is also critical to note that as the world evolves, climate change will continue to pose greater threats to population health. While some experts have predicted the emergence of more serious infectious diseases as a result of rising global temperatures, others have also highlighted that the growing intensity of climate-related disasters and hazards will erode supply chain resiliency, causing greater disruption in an already fragile environment. With this in mind, the industry should also increasingly prioritise the deployment of sustainable solutions, leveraging digital solutions and renewable energy sources to decarbonise supply chains and reduce their impact on our world.<br /> <br /> <span><strong>Where the future lies for equitable access to healthcare</strong></span></p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">To ensure that high-quality healthcare continues to reach patients in both developed and developing nations, the pharmaceutical industry needs to continue to work towards holistic and comprehensive solutions that can address gaps in the ecosystem. With companies continuing to innovate for the improvement of healthcare, it is up to the collective effort of individual players, both private and public, to ensure that its benefits can be reaped by all.<br /> <br /> <em><span><strong>References</strong></span></em></p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;"><em>1. Lim MY, Kamaruzaman HF, Wu O, Geue C. Health financing challenges in Southeast Asian countries for universal health coverage: a systematic review. Archives of Public Health. 2023 Aug 17;81(1):148.</em><br /> <em>2. Duroseau B, Kipshidze N, Limaye RJ. The impact of delayed access to COVID-19 vaccines in low-and lower-middle-income countries. Frontiers in public health. 2023 Jan 12;10:1087138.</em><br /> <em>3. Ulep VG. Strengthening health systems to address inequities in COVID-19 vaccine access in the Asia-Pacific region: special series on trade and health.</em><br /> <em>4. Upton J. The impact of war on drug supply chain. MJH Life Sciences; Available from:&nbsp;</em><a href="https://www.pharmaceuticalcommerce.com/view/the-impact-of-war-on-drug-supply-chain" target="_blank" title="https://www.pharmaceuticalcommerce.com/view/the-impact-of-war-on-drug-supply-chain" rel="noopener noreferrer" style="color: #007bff;"><em>https://www.pharmaceuticalcommerce.com/view/the-impact-of-war-on-drug-supply-chain</em></a><br /> <em>5. Miller FA, Young SB, Dobrow M, et al. Vulnerability of the medical product supply chain: the wake-up call of COVID-19BMJ Quality &amp; Safety 2021;30:331-335.</em><br /> <em>6. Patz JA, Epstein PR, Burke TA, Balbus JM. Global climate change and emerging infectious diseases. Jama. 1996 Jan 17;275(3):217-23.</em><br /> &nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">This article was published in&nbsp;<a data-auth="NotApplicable" data-linkindex="0" href="https://clicktime.symantec.com/15tpDMJpL6zH89FBJRzqt?h=9v-x-rJEr2bX3PzaRZxnZkV7dDMdZMIXbIWJxF4F8bg=&amp;u=https://www.asianhhm.com/facilities-operations/importance-driving-innovative-efficient-solutions" target="_blank" rel="noopener noreferrer" style="color: #007bff;">Asian Hospital &amp; Healthcare Management</a>.</p>

Zuellig Pharma acquires Cialis® (Tadalafil) and Alimta® (Pemetrexed) from Lilly in select ASEAN markets

<p style="color: #212529; background-color: #ffffff; margin-bottom: 1rem;">Singapore, 5 February 2024<br /> <br /> Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that it has completed the acquisition of two brands, Cialis&reg; (Tadalafil) and Alimta&reg; (Pemetrexed), from Eli Lilly and Company (&ldquo;Lilly&rdquo;) for select ASEAN markets, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines and Thailand, via its wholly-owned subsidiary, Zanovex Pte. Ltd. (&ldquo;Zanovex&rdquo;). Zanovex will own the trademarks and marketing authorisations, and license manufacturing know-how for Alimta&reg;, an established chemotherapy drug for the treatment of a certain type of non-small cell lung cancer and malignant pleural mesothelioma, and Cialis&reg;, a leading men&rsquo;s health product for the treatment of erectile dysfunction.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;"><a href="https://www.zuelligpharma.com/solutions/zp-therapeutics">ZP Therapeutics</a>, the commercial division of Zuellig Pharma, will promote the two brands in the relevant markets. Prior to the acquisition, ZP Therapeutics was responsible for the promotion and distribution of the brands as part of a broader, long-term strategic partnership with Lilly in Brunei, Indonesia, Malaysia, Philippines and Thailand.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">&ldquo;This acquisition marks a major milestone in the evolution of Zuellig Pharma to becoming an integrated healthcare solutions company. It demonstrates the increasing strength of ZP Therapeutics, which has extensive in-market expertise and capabilities in driving growth of healthcare products in Asia. We look forward to further expanding our commercial presence in the region through meaningful strategic partnerships with the world&rsquo;s leading biopharma companies as we remain focused on our purpose of making healthcare more accessible to communities in Asia,&rdquo; said John Graham, Group CEO, Zuellig Pharma.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;"><span><strong>About Zuellig Pharma</strong></span></p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;"><span><strong>Zuellig Pharma</strong></span>&nbsp;is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;"><span><strong><a href="https://www.zuelligpharma.com/solutions/zp-therapeutics">ZP Therapeutics</a></strong></span>, a division of Zuellig Pharma, is the commercialisation partner of choice for the healthcare industry with offices in 13 countries across Asia and over 2,500 associates. A catalyst in improving patient journeys and healthcare outcomes through commercial excellence, robust in-market capabilities and strong ethical principles, ZP Therapeutics is a trusted partner for expanding patient access and providing innovations to the healthcare community.<br /> <br /> For more information, visit: <a href="https://www.zuelligpharma.com/">https://www.zuelligpharma.com/</a><br /> &nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;"><span><strong>Zuellig Pharma Contact Information</strong></span></p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Angelene Chong<br /> Zuellig Pharma<br /> achongam@zuelligpharma.com</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Sandpiper<br /> zuelligpharma@sandpipercomms.com</p>

Zuellig Pharma CEO John Graham appointed a member of 2024 Board of the US-ASEAN Business Council

<p><span style="color: #212529; background-color: #ffffff;">Zuellig Pharma CEO John Graham has been appointed a member of the 2024 Board of the&nbsp;</span><a data-auth="NotApplicable" data-linkindex="0" href="https://www.usasean.org/" target="_blank" rel="noopener noreferrer" style="color: #007bff; background-color: #ffffff;">US-ASEAN Business Council</a><span style="color: #212529; background-color: #ffffff;">, which steers regional shifts with research and analysis of economic, environmental, financial, political, and social conditions in the 10 nations of ASEAN.<br /> </span></p> <p><img alt="" height="310" width="534" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/About-Us/Leadership/John-Graham-CEO-Zuellig-Pharma.jpg" /></p> <p> <p style="color: #212529; background-color: #ffffff; margin-bottom: 1rem;">In its 40th&nbsp;year in 2024, the US-ASEAN Business Council has spearheaded efforts that highlight regional gaps and opportunities across individual sectors such as biopharma and healthcare. Initiatives like white papers, dialogues and meetings help to engage key stakeholders on urgent issues.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">As Zuellig Pharma drives efforts towards our key goals this year, meaningful dialogues and key insights from stakeholders can strengthen directives that can elevate healthcare strains across the region.</p> </p>

Zuellig Pharma and Substipharm Biologics partner to expand access to IMOJEV® vaccine for Japanese encephalitis across Asia

<p style="color: #212529; background-color: #ffffff; margin-bottom: 1rem;"><span>Singapore, 16 January 2024</span><br /> <br /> Zuellig Pharma, a leading healthcare solutions company in Asia, has announced its commercialisation partnership with pharmaceutical company Substipharm Biologics, to expand access of the IMOJEV&reg; Japanese encephalitis vaccine across nine markets in Asia, including Brunei, Cambodia, Hong Kong, Malaysia, Myanmar, Philippines, Singapore, Taiwan and Vietnam.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Japanese Encephalitis (JE) is transmitted with mosquitoes and causes inflammation in the brain and is the leading cause of vaccine-preventable encephalitis in Asia. The disease currently has no treatment except for the preventative protection provided by the JE vaccine such as IMOJEV&reg;.&nbsp;&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Under the agreement, Zuellig Pharma will provide marketing and distribution support for the IMOJEV&reg; JE vaccine for Substipharm Biologics across Singapore, Hong Kong, Malaysia, Philippines, Vietnam, Cambodia and Myanmar. In addition to the current warehousing and distribution (W&amp;D) agreement with Substipharm Biologics for Brunei and Thailand, Zuellig Pharma will now also provide W&amp;D and sales and marketing support to Substipharm Biologics in Taiwan. This is bolstered by the capabilities of ZP Therapeutics, a division of Zuellig Pharma, which has extensive and proven in-market expertise in furthering access to healthcare products in Asia.&nbsp;&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">&ldquo;As a leading healthcare solutions company, we are committed to expanding access to healthcare and meeting evolving healthcare needs in the region. This partnership with Substipharm Biologics is yet another testament to our commitment to provide access to high-quality and affordable vaccines to communities around the region, supported by our strong understanding of the healthcare landscape in Asia,&rdquo; said John Graham, CEO, Zuellig Pharma.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">&ldquo;ZP Therapeutics&rsquo; partnership with Substipharm Biologics is an important milestone as it expands the availability of IMOJEV&reg; to patients all over Asia. Our experience and deep expertise in vaccines, will ensure we provide critical support for doctors for this preventive vaccine for JE, especially for working populations in rural areas, where JE is a serious threat,&rdquo; commented Rehan Saghir, Executive Vice President of ZP Therapeutics.&nbsp;&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">&ldquo;As a partner that shares our vision of providing high quality, affordable medicines and healthcare solutions to patients, Substipharm Biologics will work closely with Zuellig Pharma to ensure that we continue to deliver life-saving, innovative products for populations in Asia and globally,&rdquo; said Fabrice Baschiera, Substipharm Biologics SA, Chief Executive Officer.&nbsp;&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">The IMOJEV&reg; vaccine was previously acquired by Substipharm SAS from Sanofi in 2022, with the company committing to investing in extending the vaccine&rsquo;s availability globally.&nbsp;&nbsp;&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;"><span><strong>About Zuellig Pharma&nbsp;</strong></span></p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multi-billion dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.&nbsp;&nbsp;&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">ZP Therapeutics, a division of Zuellig Pharma, is the commercialisation partner of choice for the healthcare industry with offices in 13 countries across Asia and over 2,500 associates. A catalyst in improving patient journeys and healthcare outcomes through commercial excellence, robust in-market capabilities and strong ethical principles, ZP Therapeutics is a trusted partner for expanding patient access and providing innovations to the healthcare community.&nbsp;&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">For more information, visit:&nbsp;<a href="https://www.zuelligpharma.com/" target="_blank" rel="noopener noreferrer" style="color: #007bff;">https://www.zuelligpharma.com/</a>&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;"><span><strong>About Substipharm Biologics&nbsp;&nbsp;&nbsp;</strong></span></p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Located in France, Substipharm is a privately owned Pharmaceutical Company specialized in targeted generics and established mature brands across Europe and Asia. Substipharm has seen a robust and steady growth in the past years throughout its internal development pipeline and thanks to its focused external acquisition approach. Substipharm has become a global Healthcare player with its dual approach for patients across the globe: we cure and we prevent diseases.&nbsp;&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">To this effect, Substipharm Biologics was established in 2022 after Substipharm's acquisition of IMOJEV&reg; (Japanese Encephalitis vaccine) from Sanofi. IMOJEV&reg; is the first vaccine that was acquired by Substipharm Biologics and is the first milestone of the development of this new franchise.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;"><span><strong>Zuellig Pharma Contact Information&nbsp;&nbsp;</strong></span><br /> Angelene Chong&nbsp;&nbsp;<br /> Zuellig Pharma&nbsp;&nbsp;<br /> <a href="mailto:achongam@zuelligpharma.com" target="_blank" rel="noopener noreferrer" style="color: #007bff;">achongam@zuelligpharma.com</a>&nbsp;<br /> Sandpiper&nbsp;&nbsp;<br /> <a href="mailto:zuelligpharma@sandpipercomms.com" target="_blank" rel="noopener noreferrer" style="color: #007bff;">zuelligpharma@sandpipercomms.com</a>&nbsp;&nbsp;<br /> <br /> <span><strong>Substipharm Biologics Contact Information&nbsp;&nbsp;</strong></span><br /> Joselito Sta. Ana, MD&nbsp;<br /> Substipharm Biologics&nbsp;<br /> jstaana@substipharmbiologics.com&nbsp;</p>

Zuellig Pharma becomes STADA Philippines’ exclusive distribution partner

<ul style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;"> <li> <p style="margin-bottom: 1rem;">Leading healthcare solutions company, Zuellig Pharma to exclusively distribute STADA Philippines&rsquo; range of consumer healthcare and prescription products in local market&nbsp;<br /> &nbsp;</p> </li> <li> <p style="margin-bottom: 1rem;">Brands benefiting from extended support and distribution include the FERN-C vitamin C range, the Oilatum skincare line, and Hyabak eye drops&nbsp;<br /> &nbsp;</p> </li> </ul> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;"><span>Manila, Philippines &ndash; 9 January 2024</span><br /> <br /> Zuellig Pharma, a leading healthcare solutions company, has been appointed as the exclusive distribution partner of STADA Philippines Inc., a fast-growing supplier of high-quality pharmaceuticals and an affiliate of Germany&rsquo;s STADA Arzneimittel AG.&nbsp;</p> <img alt="" height="914" width="1280" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-becomes-STADA-Philippines-exclusive-distribution-partner/Zuellig-Pharma-STADA-contract-signing-Zuellig-Pharma-Philippines-Healthcare-Distribution-Partner.jpg" /><br /> <p style="color: #212529; background-color: #ffffff; margin-bottom: 1rem;">Effective 1 January 2024, Zuellig Pharma will be the sole partner for distributing STADA&rsquo;s portfolio in the Philippines, leveraging its heritage and reach as a local market leader across over 6,000 pharmacies, supermarkets, hospitals and clinics. This partnership will play a pivotal role in expanding access to STADA's flagship brands in the over-the-counter (OTC) and consumer brand categories, as well to prescription medicines, particularly in ophthalmology, with more than 70 stock-keeping units (SKUs) being distributed as a start.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">In particular, the partnership is expected to broaden distribution and promotion of established consumer healthcare brands such as the FERN-C vitamin C range and the Oilatum skincare line. It will also support ophthalmic brands including Hyabak eye drops and make available to the market essential generic medicines in categories such as antibiotics and cardiovascular therapies within STADA&rsquo;s portfolio.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">&ldquo;We are excited to partner with STADA to make quality medicines across all segments of healthcare more accessible for Filipinos across the country. As a leading healthcare solutions company, we are confident that our longstanding presence in the Philippines and our strong in-market capabilities will enable us to continue to meet the needs of the population,&rdquo; said Jannette A. Jakosalem, Zuellig Pharma&rsquo;s Managing Director for the Philippines.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">St&eacute;phane Jacqmin, STADA&rsquo;s Head of Emerging Markets, explained: &ldquo;The Philippines is a key strategic market within STADA&rsquo;s ambitious growth plans in South-East Asia. This partnership with Zuellig Pharma will substantially drive the growth of our portfolio in the Philippines and will enable greater access for our products in the market.&rdquo;&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Paolo Valenzuela, General Manager of STADA Philippines, expressed his confidence in the agreement, stating: &ldquo;STADA is a trusted partner in the pharmaceutical industry with a legacy spanning more than 125 years. We are confident that Zuellig Pharma&rsquo;s extensive network and its proven track record in pharmaceutical distribution and healthcare services will be pivotal in helping us enhance our reach and capabilities within the Philippines. This alliance will elevate our business to the next level and enable us to deliver on our growth ambition as a key player in the market.&rdquo;&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Founded by German pharmacists more than 125 years ago, STADA has grown to become a leading supplier of medicines and healthcare products in Europe, as well as a fast-growing player in emerging markets such as the Middle East and North Africa (MENA) region, Vietnam, China and the Philippines.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Through strong local brands, STADA has become Europe&rsquo;s fourth-largest consumer healthcare company by sales, including as market leader in Germany.&nbsp; With almost 20 production sites, predominantly in Europe, STADA is also Europe&rsquo;s fourth-largest provider of prescription generic medicines and a pioneer in biosimilars, with a growing Specialty portfolio in therapeutic areas such as dermatology, nephrology, ophthalmology, rheumatology and Parkinson&rsquo;s disease.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;"><span><strong>About Zuellig Pharma&nbsp;</strong></span><br /> Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multi-billion dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.&nbsp;&nbsp;&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">&nbsp;<br /> <span><strong>About STADA Philippines and STADA Arzneimittel AG&nbsp;</strong></span>&nbsp;<br /> STADA Philippines is an affiliate of STADA Arzneimittel AG, a trusted and reliable partner in Europe for more than 125 years. It is a leading manufacturer of high-quality pharmaceuticals with a long-standing heritage rooted in pharmacies. STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2022, STADA achieved group sales of EUR 3,797.2 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 884.7 million. As of 31 December 2022, STADA employed 13,183 people worldwide.&nbsp;<br /> <br /> &nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Zuellig Pharma Contact Information:&nbsp;&nbsp;<br /> <br /> Angelene Chong&nbsp;&nbsp;<br /> Zuellig Pharma&nbsp;&nbsp;<br /> <a href="mailto:achongam@zuelligpharma.com" target="_blank" rel="noopener noreferrer" style="color: #007bff;">achongam@zuelligpharma.com</a>&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">STADA information for journalists:&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">STADA Arzneimittel AG - Media Relations&nbsp;<br /> Stadastrasse 2-18&nbsp;<br /> 61118 Bad Vilbel - Germany&nbsp;&nbsp;<br /> Phone: +49 (0) 6101 603-165&nbsp;<br /> E-Mail:&nbsp;<a href="mailto:press@stada.de" target="_blank" rel="noopener noreferrer" style="color: #007bff;">press@stada.de</a>&nbsp;&nbsp;<br /> Or visit us on the Internet at&nbsp;<a href="http://www.stada.com/press" target="_blank" title="http://www.stada.com/press" rel="noopener noreferrer" style="color: #007bff;">www.stada.com/press</a>&nbsp;&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">STADA information for capital market participants:&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">STADA Arzneimittel AG - Investor &amp; Creditor Relations &nbsp;<br /> Stadastrasse 2-18&nbsp;<br /> 61118 Bad Vilbel &ndash; Germany&nbsp;<br /> Phone: +49 (0) 6101 603-4689&nbsp;<br /> Fax: +49 (0) 6101 603-215&nbsp;<br /> E-mail:&nbsp;<a href="mailto:ir@stada.de" target="_blank" rel="noopener noreferrer" style="color: #007bff;">ir@stada.de</a>&nbsp;&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Or visit us on the Internet at&nbsp;<a href="http://www.stada.com/investor-relations" target="_blank" title="http://www.stada.com/investor-relations" rel="noopener noreferrer" style="color: #007bff;">www.stada.com/investor-relations</a>&nbsp;&nbsp;</p>

Zuellig Pharma partners with ACEN RES to supply 100% renewable energy to two key distribution facilities in the Philippines

<p>Zuellig Pharma, Asia’s leading healthcare solutions company, has recently signed a new strategic partnership with ACEN Renewable Energy Solutions (ACEN RES), the retail electricity arm of ACEN, to supply 100% renewable energy to power two major distribution facilities in the Philippines – the Santa Rosa Distribution Center and Canlubang Distribution Center.  </p> <p>With the shift to 100% renewable energy from ACEN, the Santa Rosa and Canlubang Distribution Centers combined will reduce its carbon dioxide (CO2) emissions by 10,600 tons each year, equivalent to the amount of CO2 absorbed by 92,739 trees in their lifetime (approximately 30 years).   </p> <p>Renewable energy sources, such as wind, solar, and hydropower, are key in the fight against climate change, producing electricity without contributing to Greenhouse Gas (GHG) emissions. The company’s Santa Rosa site had earlier been certified as a Leadership in Energy and Environmental Design (LEED) facility with its use of renewable energy to support the requirements of its operations. </p> <p>This partnership falls under the Retail Competition and Open Access (RCOA) programme, a government initiative allowing high power-consuming end-users to choose their electricity suppliers. RCOA provides businesses such as Zuellig Pharma the opportunity to opt for renewable energy supply, solidifying their commitment to sustainability. </p> <p>ACEN RES provides a seamless transition to renewables of businesses without them incurring additional equipment costs or causing any power interruptions, bolstering their customers’ sustainability goals. </p> <p>Miguel de Jesus, chief operating officer of ACEN’s Philippine operations and head of the commercial operations group, said: "ACEN is thrilled to join forces with Zuellig Pharma, a company that shares our robust commitment to sustainability. We are proud to support Zuellig Pharma by powering their operations with clean, renewable energy." </p> <p>Jannette Jakosalem, market managing director, Zuellig Pharma Philippines said, “The switch to renewable energy for two key distribution facilities in the Philippines is an important milestone for us, as we work towards reducing our impact on the environment and our carbon footprint across our operations and supply chains. This is a clear testament to our dedication in combating climate change. We have a long-standing commitment to build a healthier and more sustainable future for all in Asia and will continue our efforts in making an impact on climate action.”  </p> <p>Earlier this year, Zuellig Pharma was also awarded the platinum medal from EcoVadis, the world’s most trusted provider of business sustainability ratings, for the third consecutive year, demonstrating its leadership in carbon management.  </p> <p>The partnership with Zuellig Pharma extends the client sectors of ACEN RES further, now covering educational institutions, industrial plants, FMCG businesses, and office buildings. It represents an important step in ACEN's mission to foster a sustainable, low-carbon future for the Philippines and the broader Southeast Asian region. </p> <p>ACEN RES is the retail electricity unit of ACEN, an Ayala company with the largest capacity of new renewable energy in the country. ACEN is also the only Filipino-owned energy company with significant renewable energy assets in the Asia Pacific region consisting of mostly solar and wind plants in Australia, Vietnam, Indonesia, and India. </p> <p>In March 2023, ACEN became the first energy company in Southeast Asia to establish a robust Net Zero roadmap, which outlines near-term and long-term emission reduction targets by 2050. This decarbonisation strategy reaffirms the company’s climate ambitions as a leader in the region’s renewable energy space. </p>

Zuellig Pharma CEO John Graham Discusses Healthcare Trends, Sustainability, and Navigating Global Challenges

<p><span style="color: #212529; background-color: #ffffff;">In a compelling interview with BioPharma APAC, John Graham, the CEO of Zuellig Pharma, delves into the dynamic landscape of healthcare. With a focus on emerging trends, sustainability, and the intricate navigation of global challenges, this discussion offers valuable insights from a prominent leader in the pharmaceutical and healthcare sectors. Join us as we explore the intersection of healthcare innovation, environmental responsibility, and Zuellig Pharma's commitment to addressing pressing healthcare needs in Asia.</span></p> <p>&nbsp;</p> <p><img alt="" height="2100" width="3360" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Consumer-Health/Zuellig-Pharma-CEO-John-Graham-Discusses-Healthcare-Trends--Sustainability-and-Navigating-Global-Challenges/Zuellig-Pharma-Healthcare-News-CEO-Healthcare-Trends.jpg" /></p> <p> <h4 style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 0.5rem; line-height: 1.2;"><cite>&nbsp;</cite></h4> <h4 style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 0.5rem; line-height: 1.2;"><cite>Can you elaborate on the evolving trends in the healthcare industry, and how factors such as technology, innovative product portfolios, and changing consumer priorities are shaping the industry's landscape?</cite><br /> &nbsp;</h4> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">We&rsquo;re seeing a definite shift in the biopharmaceutical space, especially with the demand for more innovative forms of healthcare to treat existing and emerging disease areas. Alongside the technological advancement, the healthcare industry has to keep up with evolving expectations of consumers who are placing greater priority on personal wellness and tailored experiences.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">There has also been an increased emphasis in ensuring healthcare access and equity in the region and globally. Rising inequality in Asia, the impact climate change will have on population health and geopolitical headwinds are all issues that will pose challenges to the future of healthcare.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Ensuring that quality healthcare remains affordable and accessible for both developed and developing markets, while mitigating the knock-on effects the industry has on the environment will create a greater need for the industry to look towards greener practices in its operations.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">&nbsp;</p> <h4 style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 0.5rem; line-height: 1.2;"><cite>With increasing concerns about climate change and sustainability, how is Zuellig Pharma addressing the call for the healthcare industry to prioritise sustainability? What specific initiatives or strategies has the company undertaken to reduce its carbon footprint and promote sustainability within the healthcare sector?</cite><br /> &nbsp;</h4> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">The environmental impact of the pharmaceutical lifecycle, from drug development to transport, distribution and disposal has long been a pain point for the industry.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">As a leading healthcare solutions company, we recognise the need to introduce sustainable solutions while at the same time ensure that we are constantly working towards making healthcare more accessible for communities in Asia. This includes embedding sustainable solutions throughout different parts of our business, including the use of renewable energy, electric vehicles and the use of transport management systems to operate more sustainably in more complex logistics networks.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">We&rsquo;ve reduced our Scope 1 and 2 emissions by 42% since 2021, with the goal of being carbon neutral by 2030, and have taken active steps towards greening our fleets and facilities, including the modernisation of our vehicles with new technologies to capture emissions and use fuel more efficiently. We also use electricity powered equipment in our warehouses and have moved most of our regional services from on-premises hosting to cloud-based data centres.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Zuellig Pharma also recognises that there is a need for players across the value chain to work together to promote sustainability across operations. This is why we also prioritise working with suppliers who demonstrate their progress and ability to reduce their carbon footprint, and why we have started to incorporate sustainability criteria within our supplier selection and contracts so that we can align with partners to achieve our carbon reduction targets.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">&nbsp;</p> <h4 style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 0.5rem; line-height: 1.2;"><cite>In light of your extensive experience in the pharmaceutical and healthcare sectors, what steps do you believe pharmaceutical and healthcare organisations can take to enhance access to healthcare while also introducing more sustainable practices? Are there any successful case studies or approaches that you can highlight?</cite><br /> &nbsp;</h4> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Having a strong vision and a clear direction for sustainability goals should be one of the defining pillars of any organisation&rsquo;s strategy to maximise the positive impact it can bring to stakeholders, communities and the planet.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">For healthcare organisations in particular, it is important that such a vision encompasses a multi-faceted approach to sustainability. Sustainability has never been a one-dimensional issue, and organisational strategy should reflect this accordingly.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">It is also important to work closely with likeminded organisations to ensure that these goals can be made a reality. Prioritising sustainable procurement processes across the supply chain, and working towards meeting compliance with sustainability regulations are all ways in which companies can deliver real, tangible impact in the industry.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Investing in the right technology and solutions to make operations more sustainable is also another way in which companies can introduce more sustainable practices. For example, we introduced a sophisticated packaging solution &ndash; eZCooler, to significantly extend the storage time of temperature-sensitive products using a unique thermal isolation system that is both reusable and 100% recyclable, without relying on external energy sources. This proved to be instrumental during the height of the COVID-19 pandemic, where cold-chain solutions coming to the forefront as vaccines urgently needed to be delivered to communities all around Asia.&nbsp;&nbsp;<br /> &nbsp;</p> <h4 style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 0.5rem; line-height: 1.2;"><cite>Zuellig Pharma has a long history in Asia, and you've been at the helm as CEO since 2020. Could you share some insights into the company's evolving journey and its commitment to furthering access to healthcare for the Asian population through climate-conscious means? What milestones or achievements are you particularly proud of in this regard?</cite><br /> &nbsp;</h4> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Since 2016, we&rsquo;ve set out to embed sustainability into every facet of our operations at Zuellig Pharma, adhering to a sustainability framework that is guided by four key themes &ndash; Setting the Highest Standards of Integrity, Nurturing Talent, Improving Health Outcomes and Respecting the Environment.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">To date, we have been awarded the Platinum medal by sustainability ratings specialist EcoVadis for the third year in a row. The award is the highest accolade to be awarded to a company for its sustainability efforts and positions Zuellig Pharma in the top 1% of all assessed companies worldwide, scoring above industry averages for all pillars.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">We have also rigorously improved our sustainability initiatives year-on-year in order to continue driving impact for our stakeholders, using rigorous ESG metrics and developing action plans to address the gaps identified in previous assessments. We are one of more than 4,000 companies across the globe to have our targets approved by Science Based Target Initiatives (SBTi), in line with our commitment to reduce direct and indirect Greenhouse Gas (GHG) emissions across our operations by 42% and reducing GHG emissions across our supply chains by 25% by 2030.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">In 2023, we were also awarded the highest score obtained in our activity group from the international non-profit organisation Carbon Disclosure Protocol (CDP). This represents the second highest level of maturity a company can reach, and ranks us above the Asia average, Global average, and Road Transport average.</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">These accolades are testament to how sustainability remains fundamental to our business, and how we&rsquo;ve steadily worked towards the long-term goals we&rsquo;ve set out for the organisation.&nbsp;&nbsp;<br /> &nbsp;</p> <h4 style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 0.5rem; line-height: 1.2;"><cite>The COVID-19 pandemic has brought unprecedented challenges to the healthcare industry. How has Zuellig Pharma navigated these challenges, and what lessons have you learned in terms of adapting to unforeseen global crises and maintaining the supply chain for critical healthcare products?</cite><br /> &nbsp;</h4> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">COVID-19 revealed the vulnerabilities in supply chains, with countries and businesses battling to manage massive disruptions. Geopolitical and macroeconomic headwinds have also resulted in a slowing of global growth, which has had effects on diverging supply chains.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Asia&rsquo;s diverse and fragmented market with varying regulatory standards and large rural communities has further underscored the need for supply chain resilience, to ensure that access to healthcare and life-saving medicines are not crippled by sudden supply or demand spikes.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">During the pandemic, our existing strong partnerships with manufacturers, governments, regulatory bodies, international organisations and the private sector enabled us to accelerate COVID-19 vaccination roll-outs, whilst maintaining access to healthcare. Zuellig Pharma supported access to over 150 million COVID-19 vaccine doses across Asia, engaging over 400 government stakeholders across the globe to carve out vaccine stock allocation to Asia.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">We believe that building good, reliable distribution networks through public-private partnerships will continue to be essential to healthcare delivery, and working with local governments and cross-sector authorities will ensure that the delivery of drugs can be maintained even amidst the most turbulent times.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">On top of this, it is also important that industry players develop innovative solutions that prioritise patient care, education and affordability through strategic collaborations. Initiatives such as end-to-end vaccination programmes, named patient programmes and enhanced disease awareness and management, which are part of Zuellig Pharma&rsquo;s Patient Care solutions, will only be possible through a multi-stakeholder approach. By working collaboratively with authorities towards the shared goal of strengthening health systems and finding more opportunities for convergence and partnership, the industry can be prepared to operate through and beyond the next global crisis.&nbsp;<br /> &nbsp;</p> <h4 style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 0.5rem; line-height: 1.2;"><cite>Given the geopolitical tensions and macroeconomic headwinds in the region, what strategies has Zuellig Pharma employed to ensure its business resilience and continued growth in such a dynamic and potentially volatile environment?</cite><br /> &nbsp;</h4> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">As a business that has been operating for more than a century, we have deep expertise and knowledge of healthcare systems and the landscape in Asia, which has enabled us to develop and refine best-in-class innovative solutions that expand access to healthcare for the markets we operate in.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">As we continue to develop new innovative solutions to address Asia&rsquo;s unmet healthcare needs, we will continue to modernise our supply chain infrastructure and develop unique data and analytics offerings that help our clients and customers improve product and care delivery for patients.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">We are also working to accelerate our digital capabilities by developing omnichannel platforms, new digital engagement tools with healthcare professionals and technology that can help to accelerate growth and efficiencies within the business.&nbsp;</p> <p style="color: #212529; background-color: #ffffff; margin-top: 0px; margin-bottom: 1rem;">Most importantly, we will continue to drive sustainability efforts to ensure that our growth is both sustainable and climate conscious, so that we can make good on our commitment to the communities we serve and the world we live in.&nbsp;</p> </p>

Zuellig Pharma awarded EcoVadis Platinum Medal for third consecutive year and rated leader in carbon management

<p><em>Singapore, 13 September 2023</em> <br /> <br /> <picture data-fileentryid="4459844"> <source media="(max-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-pharma-ecovadis-sustainability-2023.png?mw=300"></source> <source media="(max-width:1000px) and (min-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-pharma-ecovadis-sustainability-2023.png?mw=1000"></source> <img alt="" data-fileentryid="4459844" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-pharma-ecovadis-sustainability-2023.png" /> </picture> <br /> <br /> &nbsp;</p> <p>Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that it has achieved the platinum medal from <a href="https://ecovadis.com/" target="_blank" rel="noopener noreferrer">EcoVadis</a>, the world&rsquo;s most trusted provider of business sustainability ratings, for the third consecutive year. In addition to the platinum certification, EcoVadis has also rated Zuellig Pharma as a leader in carbon management, which demonstrates its best-in-class greenhouse gas (GHG) management system and strong decarbonisation ambition with approved science-based targets.</p> <p>In 2023, Zuellig Pharma received an overall EcoVadis score of 82, compared to a global and Asia average of 48 and 33 points respectively. Zuellig Pharma&rsquo;s work in human rights and sustainable procurement, alongside its work to reduce carbon emissions was recognised by EcoVadis in particular, placing it among the top 1% of all organisations evaluated.</p> <p>Since 2020, Zuellig Pharma has achieved marked improvement in its overall EcoVadis score with a total increase of 18 points, while other organisations increased their scores by 1.7 points on average in the same duration. The company has been rated consistently above the industry standard across all four pillars which include environment, labour and human rights, ethics and sustainable procurement.</p> <p>&ldquo;This recognition by EcoVadis for the third year in a row is a testament to our long-standing commitment to sustainability, as we strive to be a world-class healthcare solutions company that builds a healthier future for Asia,&rdquo; said John Graham, CEO, Zuellig Pharma.</p> <p>&ldquo;A major contributor to the success of our sustainability efforts is ensuring year-on-year improvements across key metrics and diligently building an action plan to address the gaps identified from the previous assessment,&rdquo; he added.</p> <p>As part of its efforts to prioritise human rights and sustainable procurement, the company launched a pilot programme &ldquo;Elevating Worker Voice&rdquo; in 2022, to monitor and address any labour risks in its supply chain in three markets including Malaysia, Indonesia, and the Philippines. Leveraging its partnership with The Mekong Club, a non-profit organisation specialising in detecting and eliminating modern slavery in Asia, a survey was conducted to understand the conditions faced by workers engaged by Zuellig Pharma&rsquo;s suppliers. With the survey results, debriefs were conducted with suppliers, alongside collaborative efforts to address shortfalls in practices. This year, Zuellig Pharma plans to establish regional guidelines for the inclusion of worker surveys as part of supplier audits and implement the programme in sites across the region.</p> <p>In 2022, the company also successfully reduced its overall greenhouse gas emissions by 31% and made progress against its Science Based Targets through initiatives such as the greening of its fleets and facilities, the migration of regional services to cloud-based data centres and partnerships with suppliers to drive emission and waste reduction. The introduction of such initiatives allowed Zuellig Pharma to readjust its operations to be more energy efficient, and successfully reduced its material value chain emissions and overall carbon footprint.</p> <p>Earlier this year, Zuellig Pharma announced its score of &ldquo;A-&rdquo; for Supplier Engagement from global carbon disclosure platform <a href="https://www.cdp.net/en" target="_blank" rel="noopener noreferrer">CDP</a>, making it the first and only company worldwide in its activity group to receive this recognition. The company was also awarded a score of &ldquo;B&rdquo; for Climate Change. CDP is a not-for-profit charity that runs the global disclosure system for investors, companies, cities, states, and regions to manage their environmental impact. Its latest Sustainability Report can be found <a href="https://www.zuelligpharma.com/documents/d/guest/zp_sustainability2022_web-res" target="_blank" rel="noopener noreferrer">here</a>.</p> <p><strong>About Zuellig Pharma</strong></p> <p>Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multi-billion dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.</p> <p>&nbsp;</p> <p><strong>Zuellig Pharma Contact Information</strong></p> <p>Angelene Chong<br /> Zuellig Pharma<br /> achongam@zuelligpharma.com</p> <p>Sandpiper Communications<br /> zuelligpharma@sandpipercomms.com</p>

Zuellig Pharma Singapore and GSK Establish Vaccine Distribution Hub to Improve Asia’s Access to Vaccines

<p>Zuellig Pharma, one of the largest healthcare services groups in Asia, today announced that it has entered into an agreement with global biopharma company, GSK, to help set up its first vaccine distribution hub in the region. The vaccine distribution hub will be headquartered in Singapore, serving 13 markets in Asia-Pacific (APAC).&nbsp;&nbsp;<br /> &nbsp;</p> <p> <picture data-fileentryid="4181113"> <source media="(max-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-Singapore-and-GSK-Establish-Vaccine-Distribution-Hub/zuelligpharma_newsinsights-GSK-Vaccine-Hub-01.jpg"></source> <source media="(max-width:1000px) and (min-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-Singapore-and-GSK-Establish-Vaccine-Distribution-Hub/zuelligpharma_newsinsights-GSK-Vaccine-Hub-01.jpg"></source> <img alt="" data-fileentryid="4181113" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-Singapore-and-GSK-Establish-Vaccine-Distribution-Hub/zuelligpharma_newsinsights-GSK-Vaccine-Hub-01.jpg" /> </picture> <br /> &nbsp;</p> <p> Under the partnership, Zuellig Pharma Singapore will provide GSK with warehousing and distribution services in cold-chain management for its vaccines. The vaccine hub will also leverage Zuellig Pharma&rsquo;s expertise in blockchain technology for China, one of GSK&rsquo;s largest APAC markets.&nbsp; The use of eZTracker, Zuellig Pharma&rsquo;s end-to-end blockchain solution, will enhance the resiliency of GSK&rsquo;s supply chain to enable greater traceability of its vaccines. This allows for better product visibility to address the growing challenge of counterfeit healthcare products in Asia.&nbsp;&nbsp;</p> <p>The vaccine distribution hub will adopt a sea transport model to reduce its supply chain carbon footprint, resulting in reduced transportation carbon emissions by at least 30%, compared to air transport. All vaccines will also be under vigorous temperature control to safeguard their integrity and quality.&nbsp;</p> <p>Tan Yan Ann, Chief Executive, Zuellig Pharma Singapore said: &ldquo;GSK has been a long-term partner of Zuellig Pharma with a strong focus on improving patients&rsquo; access to healthcare. We are delighted to be able to support them in the management of their Asia supply chain. With each market having their own unique requirements, the strategic location of GSK&rsquo;s vaccine hub will allow it to respond quickly to the changing healthcare landscape. Combining our cold chain expertise and proven blockchain solution, we look forward to building a stronger and more resilient supply chain with GSK to make healthcare more accessible in the communities we serve in the region.&rdquo;&nbsp;&nbsp;</p> <p>Robert Kruit, EVP Strategic Partnerships &amp; Business Development, Zuellig Pharma said: &ldquo;With the launch of GSK&rsquo;s regional vaccine distribution hub, the strategic partnership between GSK and Zuellig Pharma delivers a profound, direct impact on vaccine availability in the region, while reducing the carbon footprint and setting a standard in supply chain traceability.&rdquo;&nbsp;</p> <p>GSK&rsquo;s vaccines portfolio is the broadest in the biopharma industry, helping protect people from diseases such as meningitis, shingles, flu, polio, measles and many more. Two million of the company&rsquo;s vaccines are administered every day, including to 40% of the world&rsquo;s children who receive a GSK vaccine each year.1&nbsp;&nbsp;&nbsp;</p> <p>David Brandt, Customer Supply Chain Lead, GSK said: &ldquo;The demand for GSK&rsquo;s vaccines in the APAC region is growing rapidly as GSK launches and grows supply of new vaccines. The new vaccines distribution hub in Singapore will become our vaccine supply gateway into the region.&rdquo;&nbsp;</p> <p>Saddam Huq, Director, Cold Chain &amp; Logistics Network, GSK said: &ldquo;This is a strategic project for GSK to drive growth and build synergies globally. The set-up of a regional distribution hub for vaccines is a major milestone for GSK distribution network, further strengthening our supply chain and contributing to our global ambition of net zero impact on climate by 2030. This partnership aligns with our purpose of getting ahead of disease together, aiming to positively impact the health of 2.5 billion people globally by the end of 2030.&rdquo;&nbsp;<br /> <br /> Reference:&nbsp;</p> <ol> <li> <p><a href="https://www.gsk.com/en-gb/company/purpose-strategy-and-culture/" rel="noopener noreferrer">www.gsk.com</a><a href="https://www.gsk.com/en-gb/company/purpose-strategy-and-culture/">: </a><a href="https://www.gsk.com/en-gb/company/purpose-strategy-and-culture/" rel="noopener noreferrer">Purpose, strategy and culture | GSK</a>. July 2023.&nbsp;</p> </li> </ol> <p> For more information, please contact:&nbsp;</p> <p><strong>Linda Siow</strong> <br /> Manager, Marketing &amp; Corporate Communications<br /> Zuellig Pharma Singapore<br /> <a href="mailto:LSiow@zuelligpharma.com" target="_blank" rel="noopener noreferrer">LSiow@zuelligpharma.com</a><br /> <br /> <strong>Lucas Tan</strong> <br /> Director, Commercial &amp; Program Management<br /> Zuellig Pharma Singapore<br /> <a href="mailto:cytan@zuelligpharma.com" target="_blank" rel="noopener noreferrer">cytan@zuelligpharma.com</a><br /> <br /> <strong>About Zuellig Pharma&nbsp;&nbsp;</strong></p> <p>Zuellig Pharma is one of the largest healthcare services groups in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multi-billion dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.&nbsp;&nbsp;&nbsp;</p> <p>Since 1939, our Singapore office has been providing world-class distribution, digital and commercial services to more than 6,000 customers domestically. In 1994, we established our regional distribution centre in Singapore, operating the largest secondary repackaging centres at our GMP-certified warehouses to support more than 30 regional clients in the pharma, biotech, medical device, and diagnostics industries. For more information, please visit <a href="https://www.zuelligpharma.com/" target="_blank" rel="noopener noreferrer">www.zuelligpharma.com</a>.&nbsp;&nbsp;<br /> <br /> <strong>About GSK&nbsp;</strong></p> <p>GSK is a global biopharma company with the ambition and purpose to unite science, technology and talent to get ahead of disease together. For further information, please visit<a href="https://www.gsk.com/en-gb/" rel="noopener noreferrer">www.gsk.com</a>.&nbsp;</p> <p>&nbsp;</p>

Interpharma Investments Limited appoints Alfonso “Chito” Zulueta as Non-Executive Chairman

<p>Interpharma Investments Limited, holding company of leading healthcare services provider Zuellig Pharma, today announced the appointment of Mr. Alfonso &ldquo;Chito&rdquo; Zulueta as Non-Executive Chairman of its Board. Effective 1 June 2023, Mr. Zulueta succeeds Mr. Patrick Davies, who stepped down after serving as Non-Executive Chairman for four years.</p> <p>Mr. Zulueta joins Interpharma Investments Limited with more than three decades of experience with Eli Lilly and Company, where he was most recently President of Lilly International, and an Executive Committee member and Corporate Officer prior to his retirement in 2021. He has a strong track record in the pharmaceutical industry and extensive experience on corporate boards and industry associations. During his career with Eli Lilly and Company, he held both regional, U.S. and global roles across various functional areas including sales, marketing, product and business development, operations, and general management.</p> <p>Mr. Zulueta said, &ldquo;Zuellig Pharma plays a unique role in the healthcare landscape in Asia, as an innovative partner in many areas across distribution and commercialisation solutions. With its rich, proven legacy and a spirit of resilience, entrepreneurship and depth, the company is well-placed for an exciting future. Patrick has been exceptional in helping steer the business through a solid period of growth. I look forward to continuing his legacy and contributing to the company&rsquo;s strategy to help achieve its mission of making healthcare more accessible in Asia.&rdquo;</p> <p>Under Mr. Davies&rsquo; leadership, Zuellig Pharma overcame a period of uncertainty and significant challenges brought about by the pandemic, including major disruptions to supply chains and pressures on healthcare systems worldwide. Mr. Davies steered the company through an important business transformation, cementing its position as an indispensable partner to the company&rsquo;s key stakeholders and the communities it serves in Asia.</p> <p>Mr. Davies said, &ldquo;The company&rsquo;s success in weathering massive challenges over the past four years is a true testament of our capabilities, collective resilience and commitment towards building a healthier future for Asia. It brings me great pride to have been part of this journey and I look forward to seeing Zuellig Pharma scale greater heights in the years to come.&rdquo;</p> <p>Interpharma Investments Limited expresses its sincerest gratitude to Mr. Davies for his valuable contribution to the Board during his four-year term and extends its warmest welcome to Mr. Zulueta.</p> <p>About Zuellig Pharma</p> <p>Zuellig Pharma (a subsidiary of Interpharma Investments Limited) is one of the largest healthcare services groups in Asia and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become an over US$15</p> <p>billion business covering 16 markets with over 13,000 employees. Our people serve over 350,000 medical facilities and work with over 500 clients, including the top 20 pharmaceutical companies in the world.<br /> &nbsp;</p> <p><strong>Zuellig Pharma Contact Information</strong></p> <p>Angelene Chong<br /> Zuellig Pharma achongam@zuelligpharma.com</p> <p>Sandpiper Communications<br /> zuelligpharma@sandpipercomms.com</p> <p>&nbsp;</p> <p><em>Singapore, May 5, 2023</em></p>

Zuellig Pharma recognised with a score of “A-” on CDP supplier engagement in industry first

<p>Zuellig Pharma, one of the largest healthcare services groups in Asia, has announced its score of &ldquo;A-&rdquo; for Supplier Engagement from global carbon disclosure platform <a href="https://www.cdp.net/en">CDP</a>, making it the first and only company worldwide in its activity group to receive this recognition. This comes on the back of scoring &ldquo;B&rdquo; on CDP Climate Change earlier in the year. Zuellig Pharma first participated in this voluntary disclosure in 2021 and has improved their Climate Change score from &ldquo;C&rdquo; to &ldquo;B&rdquo;, and their Supplier Engagement score from &ldquo;B&rdquo; to &ldquo;A-&ldquo; within a year. Their improved scores set them well above the global, Asia and industry averages and is a testament to their long-standing commitment to sustainability and driving climate action across the value chain.&nbsp;</p> <p>CDP is a not-for-profit charity that runs the global disclosure system for investors, companies, cities, states and regions to manage their environmental impact.&nbsp;</p> <p>&ldquo;These ratings affirm our decarbonisation efforts in an industry where 70% of greenhouse gas emissions sit within the value chain. We are proud to receive recognition and are grateful to our suppliers for their commitment to sustainable business, which has enabled us to navigate the complexity of coordinating these efforts in an operationally diverse environment. We will continue working closely with our clients, customers and suppliers to drive our sustainability agenda and make a positive impact on the communities we serve,&rdquo; said John Graham, CEO, Zuellig Pharma.</p> <p><strong><img alt="" height="538" width="1020" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Healthcare-Providers/Zuellig-Pharma-recognised-with-a-score-of-A--on-CDP-supplier/zuellig-pharma-news-insights-cdp-inner-image.png" /><br /> <br /> <br /> Active engagement with suppliers to reduce carbon footprint</strong></p> <p> Zuellig Pharma is the first and only company worldwide in their activity group (Road Transport) to make it to the A-list for CDP&rsquo;s Supplier Engagement Rating (SER). The SER acknowledges that purchasing organisations have the potential to incentivise significant environmental changes in their supply chain through supplier engagement best practices. A significant portion of Zuellig Pharma&rsquo;s efforts to reduce greenhouse gas (GHG) emissions focuses on Scope 3 emissions through procurement policies. The company incorporates sustainability criteria within its supplier selection processes and contracts and prioritises working with suppliers that demonstrate commitment to reducing their carbon footprint. Suppliers are required to report the carbon impact of activities, and the company&rsquo;s largest suppliers have environmental targets that Zuellig Pharma maps against its own carbon reduction targets.&nbsp;</p> <p>Sustainability initiatives with suppliers to reduce Scope 3 emissions include the use of biofuel and newer generation engines, driver training and monitoring to promote emission-reducing driving habits, innovative insulation in cold trucks to reduce the use of aircon blowers, aerodynamic improvement to achieve fuel savings, and constant refinement of asset utilisation rates and routes. These efforts are tracked and assessed on the IntegrityNext platform, which provides insights on suppliers' sustainability practices and enables Zuellig Pharma to flag improvement areas and mitigate issues through ongoing dialogue and education.</p> <p>In addition, Zuellig Pharma runs Sustainability Development Programmes to drive concrete and time-bound actions to improve sustainability performance. It also works with suppliers on one-off sustainability initiatives, such as co-developing the use of solar panels to power refrigeration units in delivery vehicles in Malaysia and launching an electric-powered fleet in South Korea to reduce its carbon footprint and increase fuel efficiency.</p> <p><strong>Organisation-wide commitment to reducing greenhouse gases recognised by CDP</strong></p> <p> The score of &ldquo;B&rdquo; on Climate Change awarded by CDP for 2022 recognises Zuellig Pharma&rsquo;s commitment to reducing absolute scope 1 and 2 GHG emissions by 42% as well as a 25% reduction in absolute scope 3 GHG emissions by 2030, in addition of its goal to be carbon neutral in its own operations by that year. These targets have also been validated and approved by the Science-Based Targets initiative (SBTi). The company has gained a comprehensive view of its total direct, downstream and upstream GHG and identified opportunities for emissions reduction by screening all Scope 3 categories listed by the GHG Protocol to identify those relevant to its activities. This has enabled it to initiate actions such as:</p> <ul> <li> <p>Reducing energy use from IT infrastructure by moving most of its regional services from on-premises hosting to cloud-based Microsoft Azure data centres, achieving greater energy efficiency of up to 93% and greater carbon efficiency of up to 98%.&nbsp;</p> </li> <li> <p>Rolling out solar panel installation starting in Taiwan and Vietnam with installation planned for Singapore, Thailand, and Cambodia in 2023. This has so far generated 5.4M kWh, covering 5% of electricity needs.</p> </li> <li> <p>Switching to electric vehicles &ndash; The company is actively moving towards greener transport fleets in selected markets. By 2030, internal combustion engine (ICE) delivery vehicles will be phased out in Singapore, while Korea will use electric vehicles for all short-distance deliveries.</p> </li> </ul> <p>Apart from CDP ratings, Zuellig Pharma&rsquo;s sustainability efforts have also been recognised with the EcoVadis Platinum certification for two years running, placing the company at the top 1% of all assessed companies worldwide and ranking it #1 globally in their industry amongst 2,800 logistics leaders. Its latest Sustainability Report can be found <a href="https://www.zuelligpharma.com/documents/d/guest/zp_sustainability2022_web-res">here</a>.&nbsp;</p> <p>&nbsp;</p> <p><strong>About Zuellig Pharma</strong></p> <p>Zuellig Pharma is one of the largest healthcare services groups in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become an over US$15 billion business covering 16 markets with over 13,000 employees. Our people serve over 350,000 medical facilities and work with over 500 clients, including the top 20 pharmaceutical companies in the world.&nbsp;</p> <p>&nbsp;</p> <p><strong>Zuellig Pharma Contact Information&nbsp;</strong></p> <p>Angelene Chong&nbsp;<br /> Zuellig Pharma&nbsp;<br /> <a href="mailto:achongam@zuelligpharma.com">achongam@zuelligpharma.com</a></p> <p>&nbsp;</p> <p>Sandpiper Communications&nbsp;<br /> <a href="mailto:zuelligpharma@sandpipercomms.com">zuelligpharma@sandpipercomms.com</a>&nbsp;<br /> <br /> <em>Singapore, April 27, 2023&nbsp;</em></p> <p>&nbsp;</p> <p>&nbsp;</p>

COVID-19 Vaccines Clinical Trial Environment

<p>The World Health Organization officially declared the coronavirus outbreak a pandemic in March 2020. By June 2021, 170 vaccine candidates for COVID-19 had been developed. Of these, 90 were being tested in human clinical trials, 30% had reached Phase 3 and selected vaccines had been authorised for emergency use. There are at least 440 clinical trials with mRNA candidates and at least 140 for viral vectors.<br /> <br /> In providing a wide range of services and fostering cooperative partnerships across all domains of healthcare, we seek to leverage the power of collaboration in service of healthcare solutions. We also continue to pursue partnerships with forward-thinking industry leaders.<br /> <br /> Together we combine our unique resources to create results that matter. Working with partners across a broad range of healthcare domains is our priority at Zuellig Pharma.</p> <p>&nbsp;</p> <p> <picture data-fileentryid="1978626"> <source media="(max-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Pharmaceutical-Companies/COVID-19-Vaccines-Clinical-Trial-Environment/blog2Xph01.jpg"></source> <source media="(max-width:1000px) and (min-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Pharmaceutical-Companies/COVID-19-Vaccines-Clinical-Trial-Environment/blog2Xph01.jpg"></source> <img alt="" data-fileentryid="1978626" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Pharmaceutical-Companies/COVID-19-Vaccines-Clinical-Trial-Environment/blog2Xph01.jpg" /> </picture> <br /> &nbsp;</p> <p> <strong>Our Roles &amp; Responsibilities in Temperature Management</strong> <br /> <br /> Zuellig Pharma has established capabilities in providing world-class temperature-controlled ecosystems consisting of warehousing facilities, packaging and temperature monitoring systems, and delivery infrastructure. We pride ourselves on our commitment to quality and maintaining product integrity, through practices that meet international regulatory standards. We are certified compliant with Good Storage and Distribution Practice, GDP and GMP (for secondary repackaging) by the British Standard Institution and have passed multiple annual Good Practice audits by clients.<br /> <br /> To ensure cold chain integrity, Zuellig Pharma has invested significantly in new solutions to mitigate the risk of temperature excursions. These range from sophisticated temperature management systems in warehouses, to packaging such as the Zuellig Pharma eZCooler, which keeps drugs at the right temperatures for up to five days. This ensures last mile<br /> <br /> integrity in Southeast Asia where the climate is humid and transportation infrastructure is limited outside of capital cities. With its phase-change coolants and vacuum insulated panels, the eZCooler provides extended retention capability and has a lifetime of four years. It is also 100% recyclable.<br /> <br /> In addition, we use temperature monitors, sensors and track and trace systems along the entire supply chain to maintain the integrity of the drugs we transport every day. Reports are generated at the end of a delivery to confirm no temperature excursions have occurred. Soon, real-time monitoring will pair with the ability to provide instant alerts if temperature trends deviate beyond the safe range so that immediate remedial action can be taken.<br /> <br /> <br /> <br /> &nbsp;</p>

Zuellig Pharma brings logistics expertise to support the Thai government in distribution of one million doses of COVID -19 vaccine Moderna donated by the US government for Thai people

<p>Zuellig Pharma announced its commitment to support the Thai Government, through the Department of Disease Control, Ministry of Public Health. Zuellig Pharma will provide warehousing and transportation services without charge for one million doses of COVID-19 Vaccine Moderna donated by the US Government, as part of its ongoing support to the country&rsquo;s key mission in achieving herd immunity.<br /> <br /> <picture data-fileentryid="2174664"> <img alt="" height="156" width="280" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Healthcare-Providers/Zuellig-Pharma-brings-logistics-expertise-to-support-the-Thai-government/ThaiGovt_Donation_Moderna.jpeg" /><br /> <br /> Dr. Opart Karnkawinpong, Director-General of the Department of Disease Control, Ministry of Public Health said &ldquo;The donation of Covid-19 Vaccine Moderna from the US Government to the Thai Government through the Ministry of Foreign Affairs will be used to serve the public&rsquo;s beneficial use with the plan to allocate the vaccines to the outbreak areas of Coronavirus 2019. The donated vaccine must not be exploited for other purposes such as re-selling. Furthermore, delivery of the vaccines across the country will require to be temperature-controlled throughout transportation process to ensure its quality being maintained and to support herd immunity building for both Thais and foreigners living in Thailand. With this specific controlled condition, it requires specialty in this area. We are pleased to receive exceptional support from Zuellig Pharma in managing logistics process of the donated vaccines for us as a part of the nation&rsquo;s mission.&rdquo;<br /> <br /> Ms. Pucknalin Bulakul, Chief Executive of Zuellig Pharma Thailand said,<br /> &nbsp;</picture> </p> <p><em>&ldquo;We are very honoured&nbsp;and proud to be a part of the supports to the government agencies in serving public benefits. We are pleased to bring our logistics capabilities and expertise in the storage and delivery of the vaccines and to maintain the quality of the donated vaccine until delivery at the destination without charge. This support is aligned with our company&rsquo;s mission in making healthcare more accessible. We are ready to collaborate with all sectors to achieve the country&rsquo;s COVID-19 vaccination plan in building herd immunity including responding to the country's re-opening policy so as to drive the economy with balance and efficiency.&rdquo;</em></p> <p> <strong>About Department of Disease Control</strong> <br /> <br /> Department of Disease Control, Ministry of Public Health is one of the government agencies, which brings significance to the advancement of public health. We aim to become a leading organization in academics and technology for disease control and prevention both locally and internationally. The Department of Disease Control also promotes collaborative efforts among local and international networks for the development of experts, knowledge and information sharing, tools, surveillance laws, disease control and prevention, health hazards, as well as specific services with the global standard.<br /> &nbsp;</p>

ZP Therapeutics ready to deliver the first shipment of COVID-19 vaccine Moderna to increase vaccine access in Thailand

<p>The Government Pharmaceutical Organisation, represented by Ms. Sirikul Matevelungsun (third from left), Deputy Managing Director, together with The Private Hospital Association, represented by Dr. Paiboon Eksaengsri (far right), Secretary-General, received the first 560,000 doses of COVID-19 Vaccine Moderna from Zuellig Pharma, led by Ms. Sunaiyanaa Kidkasetpaisal (second from left), General Manager, ZP Therapeutics, and Ms. Pucknalin Bulakul (far left), Chief Executive, Zuellig Pharma Thailand, at Suvarnabhumi Airport. The shipment was delivered by Lufthansa Airways, flights LH 772.<br /> <br /> ZP Therapeutics is ready to deliver the first shipment of 560,000 doses of COVID-19 Vaccine Moderna to the Government Pharmaceutical Organisation (GPO) for distribution to the Private Hospital Association in an effort to increase access to alternative vaccines for the people of Thailand.<br /> <br /> Ms. Sunaiyanaa Kidkasetpaisal, General Manager at ZP Therapeutics, Zuellig Pharma Thailand, stated, "The company is pleased to announce that we are ready to deliver the first batch of 560,000 doses of COVID-19 Vaccine Moderna as previously stated. The remaining of the 1.9 million doses will continue to be delivered until the end of 2021 as informed by Moderna. The other 6.8 million doses are expected to be handed over in the first quarter of 2022. ZP Therapeutics draws upon our unparalleled commercialisation capabilities, expertise, and experience to support the Thai government and private healthcare institutions in advancing national efforts for COVID-19 vaccination programmes."<br /> <br /> Ms. Pucknalin Bulakul, Chief Executive at Zuellig Pharma Thailand, said, "We will draw upon our capabilities and expertise in storage and distribution of pharmaceutical products and vaccines, leveraging on our cutting-edge technologies in supply chain and cold-chain logistics. This is to ensure the quality of the COVID-19 Vaccine Moderna, which needs to be stored at the controlled temperature of -20&deg;C during transportation to hospitals and vaccination sites. We put our efforts to accelerate the vaccine distribution to various areas across the country."<br /> <br /> Ms. Sirikul Matevelungsun, Deputy Managing Director, Government Pharmaceutical Organisation, said, "The Government Pharmaceutical Organisation is appointed as the government agency for the procurement of alternative vaccines to increase vaccine access for Thai people. We would like to thank the Private Hospital Association and Zuellig Pharma for their support in pushing forward for the availability of the vaccines. After the vaccines undergo all the necessary quality inspection and testing, Zuellig Pharma will then distribute the vaccines to private hospitals according to the portion of the pre-ordered quota."<br /> <br /> "Since the beginning of the COVID-19 pandemic, the Government Pharmaceutical Organisation has committed to performing all relevant missions in securing the supply and procurement of medicines, vaccines, medical devices and protection equipment. We support the country&rsquo;s public health system to reduce infection and mortality rates, in an effort to drive the economy forward,&rdquo; said the Deputy Managing Director.<br /> <br /> Dr. Chalerm Harnphanich, Chairman of The Private Hospital Association, added, "The Association had previously notified each hospital on the preparation of vaccination services for those who have made the bookings. We will continue working closely with the Government Pharmaceutical Organisation and ZP Therapeutics to follow up on the next batch of delivery to ensure that we bring adequate supply of the vaccines to the people of Thailand as soon as possible. The COVID-19 Vaccine Moderna is a highly sought-after alternative vaccine. According to clinical trials, two-dose primary series of the vaccine showed up to 94% efficacy in preventing symptomatic COVID-19 infection in adults. Results from real-world effectiveness demonstrated the vaccine reduces risk of infection by 91% for fully vaccinated people, with recent studies showing the vaccine to remain effective against the Delta variant."<br /> &nbsp;</p>

Zuellig Pharma and GW Pharmaceuticals sign a partnership agreement in Taiwan

<p>Zuellig Pharma announced a new partnership with GW Pharmaceuticals (GW) to support access to cannabis-based medicines in Taiwan. GW, part of Jazz Pharmaceuticals plc, is a world leader in discovering, developing, and delivering regulatory approved cannabis-based medicines.<br /> <br /> As part of GW&rsquo;s commitment to bringing its medicines to patients and clinicians in Taiwan, it has chosen Zuellig Pharma Taiwan to support appropriate access to GW&rsquo;s medicines given Zuellig Pharma&rsquo;s position as the leading medical solutions provider with an end-to-end medical service value chain. From clinical trials, distribution, pharmaceutical commercialisation to patient care services, Zuellig Pharma Taiwan has excellent coverage in pharmaceutical channels, especially in GP and drug stores.<br /> <br /> John Chou, Managing Director of Zuellig Pharma Taiwan said, &ldquo;We are honored to have the opportunity to work with GW Pharmaceuticals when the company decided to enter Asia&rsquo;s markets. Our company has been present in Taiwan for more than 30 years and has been the business partner of choice for biotechnology companies seeking business expansion in the region. Through this partnership, we hope to make new and innovative therapeutic drugs available for Taiwanese patients, thereby fulfilling Zuellig Pharma&rsquo;s mission of making healthcare more accessible in Taiwan.&rdquo;<br /> <br /> Joseph Lai, General Manager of ZP Therapeutics, Zuellig Pharma Taiwan shared, &ldquo;ZP Therapeutics has a deep understanding of the Taiwanese market, healthcare ecosystem and an extensive healthcare commercial team. ZP Therapeutics will continue to deepen our presence in the fields of diabetes, immunology, oncology, vaccines and rare diseases.<br /> <br /> &ldquo;Formally establishing our partnership with Zuellig Pharma in Taiwan underscores our long-term commitment to supporting Taiwanese patients and physicians and furthers GW&rsquo;s mission to bring innovative medicines to patients with high unmet need&rdquo; said Chris Tovey, Jazz&rsquo;s Chief Operating Officer. &ldquo;Our drive to find solutions for complex medical problems has resulted in the regulatory approval of world-first treatments in a new frontier of medicine.&rdquo;<br /> <br /> <picture data-fileentryid="2174785"> <img alt="" height="165" width="280" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-and-GW-Pharmaceuticals-sign-a-partnership-agreement-in-Taiwan/GWPharma_ZPTW2021_web.png" /><br /> <br /> <br /> <strong>About GW Pharma Limited</strong> <br /> <br /> GW Pharmaceuticals (GW), a subsidiary of Jazz Pharmaceuticals plc, has established a world-leading position in cannabinoid science and medicine. Founded over two decades ago in response to significant unmet patient need, patients remain our key focus and improving their quality of life, our motivation. GW&rsquo;s pioneering work has led to the regulatory approval of world first, potentially life changing, cannabis-based medicines. Our continued dedication has resulted in the treatment of thousands of patients with our medicines in the UK and around the world. In 2021, GW received the Queens Award for Enterprise in Innovation in recognition of its innovative and ground-breaking work in developing prescription cannabis-based medicines. GW was acquired by Jazz Pharmaceuticals in May 2021.<br /> <br /> <strong>About Jazz Pharmaceuticals plc</strong> <br /> <br /> Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases&mdash;often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.</picture> </p>

Updates on the first shipment of COVID-19 vaccine Moderna to Thailand

<p><a rel="noopener noreferrer" href="https://www.zuelligpharma.com/solutions/zp-therapeutics" target="_blank">ZP Therapeutics</a>, a division of <a rel="noopener noreferrer" href="https://www.zuelligpharma.com/" target="_blank">Zuellig Pharma</a> and the official partner of Moderna in Thailand, confirms that the first shipment of 560,000 doses of COVID-19 Vaccine Moderna will arrive in Thailand within 5 November 2021, based on the latest schedule provided by Moderna. We had already put into place all measures to pick up and deliver the batch to Thailand as soon as they are made available to us.<br /> <br /> The company is also on track per the confirmation provided by Moderna to deliver the remaining of the 1.9 million doses of COVID-19 Vaccine Moderna to Thailand within the fourth quarter of 2021. The other 6.8 million doses are still expected to be delivered in the first quarter of 2022.</p> <p> <picture data-fileentryid="3633940"> <source media="(max-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Pharmaceutical-Companies/Updates-on-the-first-shipment-of-COVID-19-vaccine-Moderna-to-Thailand/zpt_thailand_moderna.jpeg"></source> <source media="(max-width:1000px) and (min-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Pharmaceutical-Companies/Updates-on-the-first-shipment-of-COVID-19-vaccine-Moderna-to-Thailand/zpt_thailand_moderna.jpeg"></source> <img alt="ZP Therapeutics delivering Moderna vaccine in Thailand" data-fileentryid="3633940" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Pharmaceutical-Companies/Updates-on-the-first-shipment-of-COVID-19-vaccine-Moderna-to-Thailand/zpt_thailand_moderna.jpeg" /> </picture> <br /> <br /> To ensure that we bring adequate and consistent supply of vaccines to the people of Thailand, ZP Therapeutics has submitted the documents to register Moderna&rsquo;s US manufacturing site with Thailand&rsquo;s Food and Drug Administration (FDA) on top of the currently approved manufacturing site on 20 October 2021. As of now, the documents are being considered by the FDA. We are working closely with the FDA for a smooth registration process and will provide further updates in due course.<br /> <br /> ZP Therapeutics remains committed to supporting the government of Thailand in achieving their mass COVID-19 vaccination goals by providing COVID-19 Vaccine Moderna to the people of Thailand.</p>

Department of disease control appoints Zuellig Pharma to handle 20 million doses Pfizer-BioNTech COVID-19 vaccines in Thailand

<p>Zuellig Pharma has been appointed by the Department of Disease Control to handle and distribute another 20 million doses of the Pfizer-BioNTech COVID-19 vaccines in Thailand. The vaccines will be stored and transported at the required temperature range of -90 degrees to -60 degrees Celsius.<br /> <br /> The team has successfully warehoused and transported 1.5 million doses of the vaccines donated to the Thai government by the United States, nationwide, in accordance with all specified standards and to the highest levels of delivery. As a result of successful delivery, the team has once again been selected by the local Department of Disease Control to continue to distribute the vaccines efficiently.<br /> <br /> <picture data-fileentryid="2174697"> <source media="(max-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Healthcare-Providers/Department-of-disease-control-appoints-Zuellig-Pharma-to-handle-20-million-doses-Pfizer-BioNTech/ZPTH_DDC_PfizerVaccines_web.jpg"></source> <source media="(max-width:280px) and (min-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Healthcare-Providers/Department-of-disease-control-appoints-Zuellig-Pharma-to-handle-20-million-doses-Pfizer-BioNTech/ZPTH_DDC_PfizerVaccines_web.jpg"></source> <img alt="" data-fileentryid="2174697" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Healthcare-Providers/Department-of-disease-control-appoints-Zuellig-Pharma-to-handle-20-million-doses-Pfizer-BioNTech/ZPTH_DDC_PfizerVaccines_web.jpg" /> </picture> <br /> <br /> <br /> Zuellig Pharma Thailand is the largest pharmaceutical cold-chain logistics provider in the country. To ensure the highest quality and integrity of the temperature-sensitive vaccines to be delivered to the Thai people, the vaccines will be safely stored in specialised freezers within the temperature range of -90 degrees and -60 degrees Celsius in accordance with the product specifications and will be transported in our innovative passive packaging solution.<br /> <br /> <picture data-fileentryid="4079559"> <source media="(max-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Healthcare-Providers/Department-of-disease-control-appoints-Zuellig-Pharma-to-handle-20-million-doses-Pfizer-BioNTech/zuellig-pharma-news-insights-moderna-pfizer-biontech-thailand-inner-image.jpg"></source> <source media="(max-width:1000px) and (min-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Healthcare-Providers/Department-of-disease-control-appoints-Zuellig-Pharma-to-handle-20-million-doses-Pfizer-BioNTech/zuellig-pharma-news-insights-moderna-pfizer-biontech-thailand-inner-image.jpg"></source> <img alt="" data-fileentryid="4079559" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Healthcare-Providers/Department-of-disease-control-appoints-Zuellig-Pharma-to-handle-20-million-doses-Pfizer-BioNTech/zuellig-pharma-news-insights-moderna-pfizer-biontech-thailand-inner-image.jpg" /> </picture> <br /> <br /> <br /> <br /> Zuellig Pharma is confident in our systems and expertise in distribution and logistics management which are specifically designed to ensure the highest quality of delivery. The team is proud to play an important part in the vaccine distribution in the COVID-19 pandemic and continuing our mission of making healthcare more accessible.</p>

Making good mental health a reality

<p><em>By Jen Garcia, VP Human Resources &amp; Corporate Communications</em> <br /> <br /> Technology like smartphones, laptops and smartwatches have blurred the lines between work and personal time even before the COVID-19 pandemic hit us almost two years ago. I remember a time when my evening jogs or weekend bike rides were refreshing bursts of me-time without the distraction of work. Family vacations were also once considered sacred. But many of us, myself included, now feel guilty for not bringing our work laptops with us on vacations. Perhaps, because I think I am expected to stay on top of my work or at the very least, stay connected even while I rest and recuperate. We compose our out-of-office notification messages in a manner that grants others permission to reach us through various channels.<br /> <br /> When the smartwatch, which I&rsquo;ve grown too dependent on, vibrates every time I receive a text message, an email or Teams chat, I can&rsquo;t bring myself to ignore it. I feel bad when I can&rsquo;t respond immediately.<br /> <br /> We have generally made a smooth transition from a face-to-face work environment to virtual and work-from-home arrangements because of the pandemic. This new normal has largely not had any adverse effect on employee productivity and may have even improved the output of work.<br /> <br /> Unfortunately, our productivity gains have inadvertently led to significant losses in terms of mental health, family time, and personal relationships. It is an issue that many companies are aware of, and HR teams have responded to this by providing initiatives in an attempt to relieve the pressures of work and make employees feel better. Relaxation packs, wellness speakers, guided mindful activities are just some of the laudable and well-intended activities that I&rsquo;ve come across. However, these are solutions that temporarily alleviate some symptoms but do not address the root cause of these stressors.<br /> <br /> At Zuellig Pharma, we encourage employees to be mindful of keeping a healthy work life balance. While there is no one-size-fits-all formula for this, leaders are encouraged to carefully prioritize work and ensure effective resource allocation to prevent frustration and burnout. Healthy interpersonal relationships are likewise encouraged as next to family and friend, colleagues at work are probably are closest support systems.<br /> <br /> When these fail, employees are provided the option to seek professional help to manage life and work stressors before these cause a negative impact on their lives. In the Philippines, health benefits cover reimbursement for therapy and counselling sessions, while in Hong Kong and Singapore, we provide hotlines for people to call when they feel the need to speak with someone about work and personal issues. In the future, we will also explore having our Zuellig Pharma managers trained in psychological first aid to better support our employees on a day-to-day basis.<br /> <br /> <picture data-fileentryid="2174841"> <img alt="" src="https://edge.sitecorecloud.io/zuelligphar3c90-zpcms-prod-4532/media/Project/Corporate/News/Consumer-Health/Making-good-mental-health-a-reality/ZP_WorldMentalHealthDay_2021_2_web.png?h=156&amp;w=280" style="display: block;margin-left: auto;margin-right: auto;" /> </picture> <br /> <br /> <br /> To commemorate World Mental Health Day on 10 October, I would like to offer three simple steps to manage stressors and ensure a good work-life balance:<br /> &nbsp;</p> <ol> <li><strong>Ask for help</strong> <br /> <br /> When experiencing difficulties because of excessive workload, tight deadlines, a lack of resources to get the job done or even domestic concerns hindering you from doing your best at work, ask for help. Sometimes, simply talking about something can point the way towards a solution. Remember that you are not alone!<br /> &nbsp;</li> <li><strong>Plan your day to incorporate rest time</strong> <br /> <br /> Taking the time to rest does not mean you are being unproductive or slacking off. It is probably unrealistic to dream about a grand two-week vacation completely detached from work. But turning your computer off by a certain time is certainly doable. Silencing your phone for a family dinner will most likely not lead to a significant business loss. As for me, I will leave my smartwatch behind the next time I go on my evening jog or weekend bike ride to enjoy the scenery.<br /> &nbsp;</li> <li><strong>Commit to check-in on each other</strong> <br /> <br /> We should not be too caught up in our lives to not notice when our workmates or our friends are having a difficult time. If we hear frustration in their voices, see sadness and worry in their eyes, notice exhaustion in their posture and their gait &ndash; let us take the initiative to check in on them. But when we ask &ldquo;How are you?&rdquo;, let&rsquo;s not settle with hearing the usual &ldquo;I&rsquo;m okay&rdquo;. Be prepared to stop, look our colleagues or friends in the eye and ask, &ldquo;No really, &ndash; how are you?&rdquo; with a sincere intention to listen and to care. Whether it is the three handles above or other ways that help us to keep our minds healthy, I hope these efforts of self-care and care for others go towards making mental health care a reality for our generation and future ones.</li> </ol>

Zuellig Pharma receives EcoVadis Platinum Sustainability rating for the year 2021

<p>Zuellig Pharma has been awarded the Platinum Medal 2021 by sustainability ratings specialist&nbsp;<a href="https://ecovadis.com/" target="_blank" rel="noopener noreferrer">EcoVadis</a>. The award is the highest accolade to be awarded to a company for its sustainability efforts and positions Zuellig Pharma in the top 1% of all assessed companies worldwide. This award also places the company in a select group of winners including 150 global multinational companies, some belonging to Fortune 500 companies.<br /> <br /> Zuellig Pharma had steadily progressed from being awarded a Silver Medal in 2020 to a Gold Medal earlier in 2021, before clinching this latest Platinum Medal. The medal was awarded after a rigorous assessment of Zuellig Pharma’s sustainability programme, covering 21 sustainability criteria across four themes, including Environment, Labour and Human Rights, Ethics and Sustainable Procurement. The company’s sustainability programme was evaluated on its policies, actions put in place to support objectives and targets, as well as results that were generated from the programme.<br /> <br /> "Sustainability is deeply embedded in the way we run our organisation and guides us in driving impact for our key stakeholders. This award, coming from the world's most trusted business sustainability rating, is a major milestone in our Sustainability journey and represents the great progress we have been making in building a healthier future for Asia. We could not have achieved this without the tireless dedication and support of every single employee in our team, and our clients, customers, suppliers and partners,” said John Graham, CEO, Zuellig Pharma.<br /> <br /> Zuellig Pharma is committed to the United Nations Global Compact and published its first ever&nbsp;<a href="https://www.zuelligpharma.com/about-us/sustainability/sustainability-gri-reports" target="_blank" rel="noopener noreferrer">GRI-aligned Sustainability</a>&nbsp;Report in 2020. The organisation is holding its second Sustainability Month this year which includes a month-worth of activities to rally stakeholders around its Sustainability Agenda.<br /> <br /> EcoVadis is a trusted provider of business sustainability ratings, creating a global network of more than 75,000 rated companies. The company’s sustainability scorecards provide detailed insight into environmental, social and ethical risks across more than 200 purchasing categories and over 160 countries.</p>

1 /0